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Abstract
Thirty-three 1,4-dihydropyridine diastereomeric pairs were synthesized and the structureactivity relationship studied in a Plasmodium falciparum in vitro model. Twenty-nine of
these derivatives contained a 6-position oxygen, with 2.31, 2.32, 2.52 and 2.53 having
single and double digit nanomolar activities. This SAR study revealed some insightful
information about the 1,4-dihydropyridine substitution pattern. Substitution at the 7position other than 3,4-dimethoxy severely reduced the activity. 4-phenyl substitution
with 2- or 4- halo or methyl formed active compounds while substitution at the 3-position
or with methoxy or conjugated aryl systems resulted in inactive compounds. The 2position was found to majorly affect the activity, with groups larger than methyl being
the most active. The other four derivatives contained a 6-position methylene, with 2.1,
2.59 and 2.60 having single nanomolar activities. Lastly, stereochemistry was revealed to
play an important role in the activity of 2.1. One stereoisomer, (+)-trans-2.1, had
subnanomolar activity in two assays. Another stereoisomer, (4S,7S)-2.1, had nanomolar
activity. The other two stereoisomers were inactive.
A series of N2,N4-disubstituted quinazoline-2,4-diamines has been synthesized and tested
against Leishmania donovani and Leishmania amazonensis intracellular amastigotes. A
structure-activity and structure-property relationship study was conducted in part using
the Topliss operational scheme to identify new lead compounds. This study led to the
identification of quinazolines with EC50s in the single digit micromolar or high
nanomolar range in addition to favorable physicochemical properties. Quinazoline 3.23
xix

also displayed efficacy in a murine model of visceral leishmaniasis, reducing liver
parasitemia by 37% when given by the intraperitoneal route at 15 mg/kg/day for five
consecutive days. Their antileishmanial efficacy, ease of synthesis, and favorable
physicochemical properties make the N2,N4-disubstituted quinazoline-2,4-diamine
compound series a suitable platform for future development of antileishmanial agents.
A similar series of N2,N4-disubstituted quinazoline-2,4-diamines has been synthesized
and tested against methicilin-resistant Staphylococcus aureus (MRSA) and multi-drug
resistant strains of Acinetobacter baumannii. Quinazolines with MICs in the single digit
micromolar or high nanomolar range were identified via SAR. In a murine model of
MRSA infection, 1x the MIC for quinazoline 4.47 allowed for the survival of all tested
mice at the end of a one week study. An in vivo model of A. baumannii was also
undertaken using a Galleria mellonella model of infection. Quinazolines 4.68, 4.70 and
4.71 afforded an increased protection of 87.5% when compared to the control
experiments, with 70% of the wax worms surviving until day three. The observed
potencies of frontrunner compounds in in vivo assays and their ease of synthesis make
N2,N4-disubstituted quinazoline-2,4-diamines a suitable platform for the future
development of anti-bacterial agents.

xx

Chapter 1: Introduction to Anti-microbials
1.1

Overview

Microorganisms, or microbes, are microscopic organisms that are found all over the
world. Microbes may be prokaryotic or eukaryotic, multicellular or unicellular. This
diverse group of organisms has played a huge role in the ecology of Earth. Bacteria
participate in the nitrogen cycle in the process of nitrogen fixation to turn inorganic
nitrogen gas to usable ammonium and nitrate. Algae and cyanobacteria perform
photosynthesis to turn carbon dioxide into sugars and oxygen. There is also the fact that
all life on earth evolved from these organisms. Microorganisms also play a more local
role in mammalian life. Bacteria within the digestive tract play a pivotal role in the health
of the human body. The treatment of sewage is undertaken with the help of a panoply of
microorganisms. The synthesis of many and large amounts of antibiotics such as
penicillin are only undertaken with the use of bacteria. Most important, a great pastime of
food and drink could not be undertaken without the help of yeast.1
Although microorganisms are known to be productive members of this planet, oftentimes
they also prey on other life forms. Eukaryotes, such as the tropical disease causing
parasites of the genera Leishmania and Plasmodium, and prokaryotes, such as the
infection causing bacteria of the genera Acinetobacter and Staphylococcus, both are
causes of human infection. Eukaryotic and prokaryotic cells can be mobile or immobile.
In the case of the aforementioned bacteria, immobility is the way of life. The eukaryotic
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Leishmania and Plasmodium, on the other hand, both display periods of mobility in their
life cycles. Leishmania promastigotes have a flagellum for movement which they lose
upon transforming to amastigotes.2 Plasmodium sporozoites are able to travel via gliding,
a mechanism characterized by the lack of any cell modification during movement. 3 These
four human pathogens will be studied in more depth within the coming sections.
1.2

Protozoa

1.2.1

Genus Plasmodium

Malaria is a parasitic disease with half of the world’s population living in affected areas. 4
Although only fifteen hundred cases of malaria are reported in the United States annually,
nearly one million people die worldwide each year from malaria and an additional two
hundred million are infected.4 These fatalities make malaria the fifth highest worldwide
cause of death following respiratory infections, HIV/AIDS, diarrheal diseases and
tuberculosis.4b Thirty five countries, thirty in sub-Saharan Africa and five in Asia,
account for 98% of the annual fatalities, while sub-Saharan Africa alone accounts for
89%.4b
Malaria is a disease that is caused in humans by protozoan parasites of the genus
Plasmodium. Five species have been found to cause malaria in humans: P. falciparum, P.
vivax, P. ovale, P. malariae, and P. knowlesi. P. falciparum and P. vivax are the two most
commonly found although P. falciparum is by far the most deadly with nearly all fatal
and severe cases of malaria, resulting from the large population of parasites which grow
inside of an infected individual.5 The parasites are transmitted by a mosquito vector of
the genus Anopheles, whereby a mosquito ingests a blood meal from an infected
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individual and the transmission occurs when the mosquito next takes a blood meal and
expels the parasites into the new host.4 The World Health Organization estimates that 219
million people were infected by malaria and that 660,000 people died worldwide due to
malaria in 2010.6 One of the major reasons for such a large population of people being
affected by this disease is that it is definitely increased in impoverished areas. Poorer
populations have a higher chance of getting malaria as they tend to live in rural areas, do
not have proper protection in place to reduce contact with mosquitoes and do not have
access to health facilities which may help them to prevent or cure the infections.6 80% of
the cases and 91% of the deaths were accounted for by sub-Saharan Africa. Along with
this figure, 86% of the deaths were children <5 years old.6
The parasites are spread by the bite of approximately twenty species of mosquitoes in the
genus Anopheles.4 When an infected female mosquito bites an animal for a blood meal,
Plasmodium sporozoites are injected into the epithelial cells. These sporozoites migrate
through the body until they end up in hepatocytes in the liver of the infected individual
(Figure 1.1).4 Here the sporozoites mature by replicating organelles and the nucleus and
become a schizont, which then divides cellularly to become merozoites. The merozoites
are then released to the rest of the body when the hepatocyte ruptures after a period of
seven days to several weeks, depending on the species.4 The newly released tens of
thousands of merozoites infect erythrocytes in the blood stream where they become
schizonts and asexually reproduce until the cells burst, restarting the erythrocyte
infection.4 A small number of merozoites transform into male and female gametocytes, a
sexual form of the parasite that may infect an uninfected Anopheles mosquito when it
takes a blood meal from the infected animal.4b, 5 In P. falciparum the gametocytes form
3

later on, with health of the host deteriorating prior to transmission. In P. vivax, however,
gametocytes form much earlier and may be transmitted prior to any clinical manifestation
of the disease.7
Inside the stomach of the mosquito, a male gamete combines with a female gamete to
form a zygote. The zygote transforms into a mobile ookinete which enters the stomach
lining and grows into a non-mobile oocyst. This oocyst is thick-walled and multiplies
until sporozoites burst from the cell. The sporozoites migrate to the salivary glands of the
mosquito and from here they are injected to a new host when the mosquito takes another
blood meal.4

Figure 1.1: The malaria parasite life cycle4b
4

As merozoites leave the liver and infect the rest of the body, signs of infection appear.
With the asexual replication of the merozoites in the erythrocytes, toxins are released
which harm the host.5 Flu like symptoms, fever, headache, chills and vomiting are the
first symptoms observed in people who are infected with malaria. Severe symptoms that
may develop include impaired consciousness, coma, prostration, acidosis, respiratory
distress, organ dysfunction including jaundice, hypoglycemia, renal failure, anemia and
abnormal bleeding.5 Early identification of the disease reduces the fatality of the severe
symptoms.
1.2.1.1 Anti-Malarials
Through the years, a number of drugs have been used to treat malaria. The cinchona
alkaloids, including quinine, may have been the first with the use of teas and extracts
from the cinchona bark during the last few centuries in South America and Europe.8 The
cinchona alkaloids, cinchonine, cinchonidine, quinine and quinidine, all display antimalarial properties but quinine became the alkaloid that moved forward because of a
higher amount present in the natural resource.8 The use of quinine waned with the onset
of new anti-malarials, including chloroquine. In recent years, quinine has returned as a
second-line treatment in combination therapy to reduce the incidence of resistance.
Chloroquine was introduced for clinical use in 1947 and has since then been used as a
staple for treatment and prevention of malaria (Figure 1.2). As a 4-aminoquinoline,
chloroquine’s mechanism of action involves the disruption of the formation of hemozoin,
a crystalline polymer made from the byproduct of hemoglobin consumption by the
parasite.9 A chloroquine-heme complex is incorporated within the polymer, capping and
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preventing the elongation of the crystal within the parasite lysosomal food vacuole.9 This
capping of the polymer allows the heme to build up in the parasite, leading to cell death
most likely via oxidative damage and disruption of the cell membrane.9 Chloroquine
resistance was first seen in the 1950’s and can be caused by an efflux mechanism. 10 The
PfCRT protein is an efflux protein located in the food vacuole membrane and is a cause
for chloroquine resistance as it actively removes quinoline molecules from the
organelle.10c, d
Pyrimethamine is a 2,4-diaminopyrimidine that began clinical use in 1953 (Figure 1.2). It
is given in combination with the sulfonamide sulfadoxine. Pyrimethamine is a
dihydrofolate reductase (DHFR) inhibitor and sulfadoxine is a dihydropteroate synthase
(DHPS) inhibitor and in combination are effective inhibitors of the synthesis of
tetrahydrofolate, a cofactor for thymidilate, purine nucleotides and certain amino acid
synthesis.11 Resistance is encountered when DHFR and/or DHPS mutations occur that
result in reduced binding and inhibition by each drug.11
Mefloquine is a quinoline derivative quite similar to quinine that was developed in the
1960’s by the Division of Experimental Therapeutics at Walter Reed Army Institute of
Research (WRAIR) and approved for use by the FDA in 1989 (Figure 1.2).12 Resistance
was first seen in Southeast Asia and it is no longer an effective treatment in certain
areas.11c,

12-13

Halofantrine is a phenanthrene that, like mefloquine, was created in the

1960’s at WRAIR and FDA approved in 1992. It was initially used in areas with
mefloquine resistance; however, it was found that it was much less effective in these
areas.11c, 12
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Atovaquone is a naphthoquinone that began clinical use in 1992 (Figure 1.2).
Atovaquone interrupts the electron transport chain in the cytochrome bc1 complex of
mitochondria which blocks the biosynthesis of pyrimidine and it also collapses the
electropotential across the mitochondrial membrane, resulting in parasite death.12,
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Atovaquone is generally given in combination therapy with proguanil, a DHFR inhibitor,
as atovaquone resistance generally occurs readily when given on its own.12, 14 Resistance
has been seen via a mutation in the gene coding for the cytochrome bc1 complex.14-15
In the late 1960’s the Chinese government invested heavily in finding anti-malarial
compounds. In 1971 the natural product artemisinin was discovered to have potent antimalarial properties through the help of ancient medicinal texts (Figure 1.2).16 In the early
1980’s this great discovery was shared with the rest of the world. A few derivatives of
artemisinin

were

found

to

have

better

properties

and

activity

including

dihydroartemisinin (DHA), artemether and artesunate.16-17 These derivatives are given in
combination known as artemisinin-based combination therapies (ACTs) as first line
treatments. Resistance to the artemisinins are hoped to be reduced this way and extend
the life of the ACTs. Current ACTs in use include artemether with lumefantrine,
dihydroartemisinin with piperaquine, and artesunate with either amodiaquine, mefloquine
or sulfadoxine-pyrimethamine.17-18 In 2006 artemisinin resistance was reported in
Southeast Asia and ACT resistance has been noted with artesunate-mefloquine in this
region.18-19 ACTs are currently the most relied on anti-malarial in use and resistance to
these combinations will be highly detrimental to many countries.
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P. ovale and P. vivax often cause relapse in patients months or years after they are
clinically cured of malaria. These two species form hypnozoites in the liver, a form of the
parasite that is dormant and unaffected by the previously shown drugs which generally
kill the erythrocytic stage of the parasites.20 Primaquine is an 8-aminoquinoline that was
first used in World War II and is able to kill these dormant parasites (Figure 1.2). It is
currently used primarily as a relapse preventer in cases of P. ovale and P. vivax in
combination with drugs that kill blood stage parasites.12, 20
Although many drugs are available to treat malaria, many are largely cost prohibitive and
this makes their use in poor endemic areas where malaria is present a large financial
burden. Current research is aimed at the production of less expensive, one time drugs that
will allow for cost effectiveness and non-extended periods of drug therapy.
1.2.2

Genus Leishmania

Leishmaniasis is a debilitating disease that is prevalent across the globe. More than
twenty species of parasite in the genus Leishmania are known to cause the disease in
humans.21 The parasites are transferred from host to host by about thirty species of
female sandfly vectors of the genera Phlebotomus and Lutzomyia that infect the host with
promastigotes when taking a blood meal (Figure 1.3).22 The flagella containing
promastigotes infect the macrophages of the mammalian host, where the flagellum is lost
and the promastigote becomes an amastigote. The amastigotes multiply within the
macrophages, increasing the parasite burden on the host and infecting new cells when the
macrophage bursts. Infected macrophages are ingested by a sandfly when a bloodmeal is
taken, resulting in a new infected vector that can transmit the disease to a new host.
8

Figure 1.2: Structures of anti-malarials
Symptoms of leishmaniasis include unsightly spontaneously healing ulcers on the skin
when cutaneous leishmaniasis presents, non-healing lesions in the mucosa when
mucocutaneous leishmaniasis is the affliction, and chronic, debilitating infection of the
reticuloendothelial system which is fatal if left untreated due to visceral leishmaniasis.

23

The majority of cases of visceral leishmaniasis, also known as kala-azar, are caused by L.
9

donovani in East Africa and Asia, L. infantum in the Mediterranean region, and L.
chagasi in Latin America.21 L. infantum and L. chagasi mainly affect children and
immunocompromised individuals and are zoonotic parasites with canines being a major
reservoir.23 L. donovani, on the other hand, is an anthroponotic parasite and affects a
broad range of ages.23 Throughout the world, 350 million people in 88 countries are at
risk of acquiring leishmaniasis.24 The World Health Organization (WHO) estimates that
1-1.5 million people acquire cutaneous leishmaniasis and five hundred thousand others
are afflicted with visceral leishmaniasis annually, with over 50,000 deaths per year.22, 24

Figure 1.3: Life cycle of the Leishmania parasite
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1.2.2.1 Anti-leishmanials
For over one hundred years, antimonials have been the drug of choice to combat
leishmaniasis. In 1912, Gaspar Vianna first reported the use of the trivalent antimonial
tartar emetic for the treatment of cutaneous leishmaniasis caused by L. braziliensis in
Brazil.25 Pentavalent antimonials such as meglumine antimoniate and sodium
stibogluconate are currently the first line drugs for treatment in many areas (Figure
1.4).23, 26 Treatment involves daily injections for up to a thirty day period.8 Problems of
using this treatment includes a high rate of resistance that has been encountered in India,
especially the state of Bihar, where up to 60% of infected individuals do not improve
with treatment.26a,

27

Since the 1960’s, amphotericin B has been the second line of

treatment for visceral leishmaniasis.8 It has a cure rate of over ninety percent, but is often
accompanied by severe side effects such as nephrotoxicity that require administration in a
hospital setting.26a,

28

Depending on the dose and formulation, the treatment regimen

varies from 3-5 days to eight weeks of administration on alternate days.21, 26a Miltefosine
is the first oral drug to be released for leishmaniasis and is currently available in India,
Germany, and Colombia.8 Miltefosine is not recommended for women who are pregnant
or may become pregnant because it is teratogenic.23, 26a Miltefosine resistance has been
demonstrated in vitro, and its long half-life in the body, the twenty-eight day treatment
regimen, as well as it previously being available over the counter in India leads to
concerns of clinical resistance.23, 26a, 29 A recent study of 567 individuals in the Bihar
state of India has been performed to determine the efficacy of miltefosine since its
induction in 2002.30 The six month cure rate was found to be roughly 90% and
gastrointestinal intolerance was encountered in 64.5% of the cases with two deaths
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related to drug toxicity.30 Patients who did not improve with treatment were cured using
amphotericin B. The authors of this study concluded that the failure rate of miltefosine
has increased in the ten years since its introduction for the treatment of visceral
leishmaniasis in India.

Figure 1.4: Common anti-leishmanials
1.3

ESKAPE Pathogens

Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter species make up an infamous
group of bacteria known as the ESKAPE pathogens. These microbes are of import due to
resistance to common anti-bacterials and the fact that they are often hospital acquired
12

infections (HAIs).31 Both Gram-positive and Gram-negative bacteria are found in the
ESKAPE pathogens. Most bacteria form a cell well outside of their plasma membrane
and the make-up of this cell wall is what determines whether they are Gram-positive or
negative (Figure 1.5).1

Figure 1.5: Cell wall of a Gram-positive and a Gram-negative bacterium
Peptidoglycan is a polymer of sugar cross-linked by short polypeptides and is found in
bacterial cell walls. Gram-positive bacteria have a comparatively large amount of
peptidoglycan and are less complex.1 The higher complexity in Gram-negative bacteria is
due to a lipid membrane outside the peptidoglycan that contains anionic
lipopolysaccharides.1 These lipopolysaccharides can be toxic and the outer membrane
creates an extra barrier that protects from host attacks and increases the difficulty for
antibiotics, especially the hydrophobic variety, to enter the cell.1 Many antibiotics inhibit
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the cross-linking of peptidoglycan and because of the smaller amount of peptidoglycan
and the presence of an outer membrane they will not affect Gram-negative species as
well.
1.3.1

Staphylococcus aureus

Bacteria of the genus Staphylococcus are Gram-positive facultative anaerobes with a 0.5
to 1 m diameter that form clusters like grapes.32 These bacteria are pathogens of
mammals, including man, and cause infections of the skin, urinary tract, blood and
respiratory system among others.
S. aureus is the leading cause of staphylococcal infection in humans. It is estimated that
20% of the world population are persistent carriers of this species in the nasal cavity and
axillae while 60% of the population are intermittent carriers.32-33 In the United States the
population of carriers is around 30%.34 S. aureus is frequently found as a nosocomial
infection (HAI), with numerous infections being encountered from hospital stays and
long term healthcare facilities every year. This bacterium causes a wide range of
infections, from minor skin infections such as pimples, impetigo, boils and other
abscesses to severe infections including osteomyelitis, pneumonia, meningitis, toxic
shock syndrome, phlebitis, mastitis and endocarditis. The severe infections are often seen
by hospital patients if they become infected during their stay. Community-acquired
infections (CA-MRSA) are caused by strains of S. aureus that are distinct from the
hospital acquired strains. Whereas the HAIs are opportunistic of unhealthy,
immunocompromised people, CA-MRSA infections can be found in typically healthy
hosts with no risk factors. CA-MRSA infections are oftentimes overwhelming, tissue
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destructive infections such as necrotizing fasciitis and fulminant, necrotizing
pneumonia.35
1.3.1.1 Staphylococcal Toxins
Numerous toxins and proteins are released by S. aureus and are the root of disease in a
host. These proteins include enzymes such as nucleases, proteases, collagenase,
hyaluronidase and lipases and the toxins that can be found are alpha-, beta-, gamma- and
delta- hemolysins, toxic shock syndrome toxin-1 (TSST-1), staphylococcal enterotoxins
(SEs), exfoliative toxins and Panton-Valentine leukocidin, most of which are released in
the post exponential growth phase.36 At this point of growth the bacteria have divided
until the amount of nutrients has reduced. Many of the toxins are believed to diminish the
immune response of the host and the proteins break down tissues into nutrients for
bacterial growth.
The staphylococcal enterotoxins and TSST-1 fall into a category of toxins known as
pyrogenic toxin superantigens (PTSAgs). The PTSAg class of toxins display at least three
properties: pyrogenicity, superantigenicity and the ability to increase the lethality of
endotoxin in rabbits up to 100,000 fold.36-37 Staphylococcal enterotoxins are also potent
emetic agents whereas TSST-1 can cross mucosal surfaces and reactivate bacterial cell
wall-induced arthritis.38 The genes for the PTSAgs are stored in pathogenicity islands
such as plasmids, bactereophages and heterologous genetic fragments.39 The mature
PTSAg has a molecular weight between 20 and 30 kiloDaltons (kDa) when released from
the cell and is a nonglycosilated polypeptide. The PTSAg toxins are found in people
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having menstrual (TSST-1) and nonmenstrual (SEs) toxic shock syndrome, sudden infant
death syndrome, food poisoning and Kawasaki syndrome.36

Figure 1.6: Crystal structure of alpha-hemolysin40
Alpha-hemolysin is a pore forming toxin that is found in numerous strains of S. aureus
and because of this is one of the most studied toxins produced.36 The mature polypeptide
has a mass of 33 kDa and is composed of 65% -sheets and 10% -helices (Figure 1.6).
It is formed in the cell during the late exponential phase of cell growth. When released
from the cell, alpha-hemolysin incorporates into host cells as oligomers, forming 1-2 nm
pores in the cell membranes as heptamers that may cause the eukaryotic cells to lyse.36, 41
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This pore allows efflux of K+ and influx of Na+, Ca2+ and small molecules less than 1
kDa, resulting in rupture of the cell due to osmotic swelling.36,

42

Alpha-hemolysin is

able to affect numerous cells including epithelial cells, erythrocytes, fibroblasts and
monocytes.36, 42
β-Hemolysin is formed by a large number of S. aureus strains, but its role in disease is
not known. Gamma-hemolysin and Panton-Valentine leukocydin (PVL), however, are
known well as affecting mammalian cells and causing disease.36 PVL is made in less than
5% of strains while gamma-hemolysin is synthesized in nearly every strain. These toxins
are similar in that they are composed of two protein subunits and affect neutrophils and
macrophages. PVL forms pores in host leukocytes, and at high concentration will cause
lytic cell death. At lower concentrations it will activate neutrophils to release granule
contents via exocytosis and secrete leukotrine B4 and interleukin 8 which causes
inflammation.35d,

36, 43

PVL is thought to be a major cause of the virulency and tissue

destruction found in CA-MRSA.44
Delta-hemolysin is a 3 kDa peptide that also causes membrane damage and cell lysis. It is
believed that delta-hemolysin acts as a surfactant in cell membranes with the release of
larger molecules as longer exposure time to the toxin is experienced. This toxin is able to
lyse erythrocytes and other cells as well as internal organelles.36
1.3.1.2 Antibiotics for Staphylococcus aureus
Alexander Fleming’s remarkable discovery of Penicillin in 1928 and the following work
by Florey, Chain and coworkers of its isolation led to a revolution in modern day
medicine.45 Previously fatal infections were curable by a simple infusion of this new
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antibiotic. It wasn’t until late 1942 and early 1943 that the new drug was mass produced,
with the British and American governments recognizing the use of antibiotics in the war
effort. In 1940 Abraham and Chain first identified and named penicillinase, a source of
penicillin resistance in S. aureus.46 Shortly thereafter penicillin resistant infections were
encountered in hospitals.35d, 47
The penicillins are a group of antibiotics that are secondary metabolites of certain species
of the fungi in the genus Penicillium. The major features of the penicillins are the βlactam and thiazolidine fused rings (Figure 1.8). β-Lactams inhibit the penicillin-binding
proteins (PBPs) that are necessary for peptioglycan biosynthesis.45 Penicillinase
hydrolyzes the β-lactam ring of the penicillins, causing deactivation (Figure 1.7). The
gene coding for penicillinase was found in a plasmid within the resistant bacteria.35d

Figure 1.7: β-Lactam deactivation by penicillinase
The late 1940’s and early 1950’s brought the discovery of cephalosporin C, a β-lactam
fused to a dihydrothiazine ring that was inactive to the penicillinase that hampered the
penicillins (Figure 1.8). The activity of this compound was much lower than the
penicillins and it wasn’t until analogues were made in the 1960’s that the cephalosporins
made headway as antibiotics.45
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In the late 1950’s after penicillin resistance was a major factor, the Beecham Research
Laboratories made semi-synthetic penicillin analogues that stemmed from 6aminopenicillanic acid (6-APA) (Figure 1.8). The idea was to add bulky side chains to
the amide functional group in order to prevent the β-lactamase enzyme from opening the
β-lactam that caused the penicillins to be ineffective. In 1959 they made methicillin, 6amino-N6-(2,6-dimethoxybenzoyl)penicillanic acid, which remained an effective
antibiotic in the presence of penicillinase.45 Cloxacillin, oxacillin, flucloxacillan and
dicloxacillan were similar analogues that displayed better blood concentrations in vivo.
Ampicillin, a penicillin derivative bearing a benzyl amine residue, was released in 1961
and is of some import as it was one of the first broad spectrum antibiotics, with antibiotic
effects in gram negative bacteria, even though it was still hydrolyzed by β-lactamases.
Amoxicillin is an analogue of ampicillin bearing a phenol that increases the oralbioavailability of the β-lactam and was released in 1972.48
In 1959, methicillin was released as a S. aureus killer that was unaffected by β-lactamase.
In 1961, however, the first strains of methicillin resistant Staphylococcus aureus (MRSA)
were encountered.35d, 49 Unlike the β-lactamase deactivation, hydrolysis of the β-lactam
ring did not occur and resistance to methicillin conferred resistance to all β-lactams.45, 50
The new strains made a new penicillin binding protein, PBP2a, that was encoded by the
mecA gene and had low affinity to β-lactams. PBPs cross link peptidoglycan chains in the
cell wall and the new membrane-bound protein is unaffected by high concentrations of all
β-lactams.51
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In the early to mid-1950’s Eli Lilly isolated a glycopeptide from a soil sample containing
bacterial growth. This glycopeptide was vancomycin, a polypeptide that displayed
activity against Gram-positive bacteria (Figure 1.8).48 Due to poor bioavailability and
side effects, vancomycin was not used as a first treatment option, especially with the
advent of non-penicillin antibiotics. This, combined with the low resistance from
susceptible bacteria, has allowed for vancomycin to be a last resort for bacterial
infections since its FDA approval in 1958.48 Teicoplanin is another glycopeptide that has
similar use to vancomycin. The glycopeptides interrupt cell wall synthesis by blocking
cross linking between peptidoglycan.45 Due to increased multi-drug resistance across
bacterial strains, glycopeptides have been used at a much higher rate in the last 25 years,
resulting in the first report of vancomycin intermediate-resistant S. aurues (VISA/GISA)
in 1997 from a MRSA strain in Japan.52 Since then, VISA and vancomycin resistant S.
aureus (VRSA) have become more prevalent across the globe.53 VRSA isolates have
been found to contain the vanA operon from vancomycin resistant Enterococcus faecalis
(VRE), showing that resistance has been transferred via plasmid between orders.51
Broad spectrum fluoroquinolones, such as ciprofloxacin, were introduced in the mid
1980’s (Figure 1.8). Fluoroquinolones act by inhibiting two enzymes that unwind
bacterial DNA, DNA gyrase and topoisomerase IV.45,

51

By 1990 mild resistance was

seen via efflux with an over expression of the multidrug NorA pump.45, 51 Nucleic acid
mutations have also resulted in amino acid substitution in the target enzymes that reduced
the binding affinity of the quinolones.51
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Figure 1.8: Structure of early antibiotics
The ability of bacteria to acquire resistance to so many drugs is multifold. The multitude
of bacteria present in an infection allows for chromosomal mutations that create
numerous phenotypes that may through randomization create a bacterium that is not
susceptible to a specific antibiotic. When bacteria are part of the normal fauna, as in the
20% of human population who are persistent carriers of S. aureus in the nasal cavities,
antibiotics that are used to treat bacterial or viral infections may affect the fauna in lower
than therapeutic doses, creating an environment with the high potential for resistance.51
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Improper use of antibiotics, such as a patient not finishing a prescription or the improper
prescribing of antibiotics for viral infections, has also played a part in resistance. Once
resistance has been found in any species of bacteria, it is possible for that resistance to be
transferred via plasmid or bacteriophage, as is the belief with VRE transfer to VRSA.51, 53
One last cause of resistance may be the ability for bacteria to from biofilms. Biofilms are
a type of bacterial growth where aggregates come together and form a layer on surfaces
that allows for protection during growth in hostile environments.54 The formation of
biofilms give bacteria an inherent resistance to any attack, be it from a host immune
system, amoeba or antibiotics. Attempts to combat an infection caused by a biofilm will
increase the chance that cells in the biofilm will grow resistance to the antibiotic in use,
since a lower concentration of drug will affect each cell.
Quinupristin and dalfopristin are two semisynthetic pristinamycins that are used in
combination and are active against MRSA and VRSA strains and FDA approved in 1999
(Figure 1.9).55 The combination works by inhibiting cytochrome P450 and prevents the
synthesis of important biochemical molecules. Resistance has been seen via efflux
mechanisms and mutation of the enzyme.55-56
Linezolid is an oxazolidinone that is active against Gram-positive bacteria and was
approved for use by the FDA in 2000 (Figure 1.9). Linezolid works by preventing protein
synthesis via binding the ribosomal 23S rRNA at doman V and preventing binding of the
initiator fMet-tRNA.57 Although serious adverse affects can be encountered, linezolid can
be substituted for vancomycin which also has serious side effects. In 2001 the first
clinical isolates were found bearing linezolid resistance.58 Resistance has been found
22

from a few mechanisms, including point amino acid mutations and methylation of the
23S rRNA by a horizontally transferred methyltransferase encoded by the plasmid
encoded crf gene.57a, 59
Daptomycin is a cyclic lipopeptide that was FDA approved in 2003 (Figure 1.9). It kills
bacteria by disrupting membrane depolarization by insertion into the cell membrane
resulting in the release of potassium ions and the cessation of biochemical functions in
the cell.60 By 2005 resistance had been encountered.61
In 2005 the FDA approved the broad spectrum tetracycline drug tigecycline for use
against Gram-postive and Gram-negative bacteria (Figure 1.9). This compound is of note
as tetracycline resistance has long been shown in Gram-positive and Gram-negative
bacteria.62 Tetracycline resistance is conferred by ribosomal protections and efflux
mechanisms and it is believed that tigecycline is able to overcome this due to a bulky
substituent on the 9-position, although activity is mildly reduced in the presence of
multidrug efflux pumps.62-63 The mechanism of action of tigecycline is the binding of the
30S ribosomal subunit, causing the inhibition of protein synthesis.62
Telavancin, a semi-synthetic lipoglycopeptide, was FDA approved in 2009 (Figure 1.9).
Telavancin has the same mechanism of action as other glycopeptides, but still displays
activity against vancomycin resistant strains, although the activity is less than that for
MRSA strains.55, 64
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Figure 1.9: MRSA anti-bacterial drugs approved by the FDA since 1999
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Ceftaroline fosamil is a broad-spectrum cephalosporin that was FDA approved in 2010
(Figure 1.9). Ceftaroline has a mechanism of action similar to other β-lactams wherein it
binds to PBPs, including PBP2a which caused resistance among β-lactams following
methicillin resistance in the 1960’s.65 It is also active against vancomycin resistant strains
of S. aureus and is generally prescribed for infections associated with CA-MRSA,
including pneumonia and severe skin infections.
Ceftobioprole is another cephalosporin that is also active against MRSA and VRSA
strains but has not gained FDA approval.66 Dalbavancin is also awaiting FDA approval
and is a lipoglycopeptide that is active against MRSA but not against VRSA strains. 55
Another glycopeptide is the semi-synthetic oritavancin that displays activity against
MRSA and VRSA strains. Clinical trials are being repeated for this compound.55

1.3.2

Acinetobacter baumannii

Acinetobacter is a genus of Gram-negative coccobacilli bacteria that is strictly aerobic,
catalase positive and oxidase negative.67 Bacteria of this genus can be found in water,
soil, and as normal fauna of animals, including human skin.68
A. baumannii is a cause of infection in the human populace. It has few virulence factors
with most infections in immunocompromised persons.67a,

68-69

Most infections

encountered include nosocomial pneumonia, meningitis, urinary tract infections, wound
infections such as surgical site infections, and bloodstream infections from central line
infections.68 People who are at risk for A. baumannii infections are those who are elderly,
are immunocompromised, have had invasive procedures, have catheters, use mechanical
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ventilation and those who have had major trauma, especially burn victims.67a One reason
for the high rate of manifestations in the hospital is that A. baumannii is able to survive
long periods of time in a dry environment, meaning that contaminated surfaces may leave
viable bacteria for several months.67a, 69-70
Along with the lipopolysaccharide of the outer membrane, one of the known virulence
factors in A. baumannii is the outer membrane protein 38 (Omp38, also known as
OmpA), a 38 kDa porin.71 Omp38 has been found to localize at the mitochondria of
epithelial cells causing mitochondrial release of apoptosis inducing factor (AIF) and
cytochrome c and resulting in apoptosis of the eukaryotes.71
1.3.2.1 Antibiotics for Acinetobacter baumannii
Since the early 1970’s, nosocomial infections of A. baumannii have shown antibiotic
resistance to compounds that it was previously susceptible such as gentamicin,
minocycline, ampicillin, carbenicillin, chloramphenicol and nalidixic acid.72 Sulbactam
and group 2 carbapenems have been the drugs of choice for multidrug resistance
strains.67a In the mid 1980’s a gene was found that encodes a carbapenem-hydrolyzing
class D -lactamase (CHDL or carbapenemase), called OXA-23.73 This enzyme is
transferred via plasmid but can be found within the chromosome and is known to
hydrolyze penicillins and some cephalosporins as well.73 This enzyme and its variants are
not very effective, but upregulation of the gene may occur resulting in resistance.67a, 74 On
its own or in collaboration with CHDLs, carbapenem resistance has also been seen by
loss of certain outer-membrane proteins that facilitate the influx of these -lactams.74 The
study of a French strain of A. baumannii has revealed the presence of resistance genes
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transferred from numerous other bacteria.75 AbaR1, an 86 kb resistance island, was found
to have 88 open reading frames that came from other organisms, 39 from Pseudomonas
spp., 30 from Salmonella spp. and 15 from Eschericia coli.75 45 resistance genes were
found within the AbaR1 resistance island.75
Carbapenems that are used as common treatments include imipenem and meropenem
(Figure 1.10). Imipenem, approved in 1985, is usually given as combination therapy with
cilastitin, an inhibitor of dehydropeptidase I that hydrolyzes imipenem.76 Meropenem was
released in 1996 and is not susceptible to this hydrolysis. The mechanism of action for
carbapenems is the same as for other -lactams, but in Gram-negative bacteria the
antibiotic enters the periplasmic space between the cell wall and outer cell membrane via
porins.76
Colistin is a polymyxin that became available for clinical use in 1959 (Figure 1.10). Its
use prior to recent years has been minimal due to nephrotoxicity and neurotoxicity side
effects.77 Polymyxins are cyclic polyamine peptides with a fatty acid side chain that
disrupt the cell membrane by the interaction of the many primary ammonium
functionalities with the anionic lipopolysaccharide on the outer membrane of Gramnegative bacteria.78 The displacement of Mg2+ and Ca2+ that form salt bridges between
the lipopolysaccharide reduces the stability of the membrane, along with the insertion of
the fatty acid side chain into the hydrophibic lipid layer, resulting in the escape of
intracellular components and finally cell death.67a, 78 Resistance to polymyxins has been
observed and the mechanism is thought to be a change in the outer membrane with the
possible reduction of lipopolysaccharides.77
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Tigecycline has shown promising results against multidrug resistant A. baumannii,
although it has a low blood serum concentration resulting in poor efficacy against
bloodstream infections.62,

67a

Tigecycline is also a poor candidate for the treatment of

urinary tract infections as it is not cleared from the body by the kidneys.67a A few cases
have been reported of tigecycline resistance occurring during therapy for these types of A.
baumannii infections.79

Figure 1.10: Gram-negative antibiotics active against Acinetobacter baumannii
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Chapter 2: 1,4-Dihydropyridines as Anti-Malarials
2.1

Hantzsch Pyridine Synthesis

The Hantzsch pyridine synthesis is an old reaction that still has applicability in today’s
chemistry.80 Classical Hantzsch syntheses employ two equivalents of β-ketoesters with
one equivalent of amine and aldehyde to form the symmetrical 1,4-dihydropyridine
derivatives (Figure 2.1). This reaction, from the late 19th century, is still used as a reliable
method for forming an assortment of 1,4-dihydropyridine products. Asymmetric
compounds may be made by using two different β-ketoesters or one β-ketoester with a βdiketone compounds.

Figure 2.1: Classical Hantzsch pyridine synthesis
This 1,4-dihydropyridine system has six  electrons delocalized over 5 atoms of the
pyridine ring, and this delocalization is extended to the carbonyls at the 3- and 5positions as well.

81

The oxidation of this system to the aromatic pyridine occurs readily

and even contact with atmospheric oxygen will cause this conversion, making the study
of the properties and characterization of dihydropyridines a difficult maneuver.81a
Nevertheless, 1,4-dihydropyridines with biological activity have been identified and
developed into FDA approved drugs.
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2.1.1

Enantioselective Syntheses of 1,4-Dihydropyridines

Recent developments in this reaction involved the formation of chiral 1,4dihydropyridines. In the early 1980’s the development of these compounds occurred with
their introduction as calcium channel blockers for the treatment of hypertension. In 1980
Shibanuma et al. reported the synthesis of (+) and (–)-nicardipine via the resolution of an
intermediate carboxylic acid (Figure 2.2).82 Aminal formation allowed for the
demethylation of one ester using sodium and 1-dimethylamino-2-propanol. Chiral
resolution occurred by recrystallization using the chiral alkaloids cinchonine or
cinchonidine to form diastereomeric salts and repeated until constant optical rotation was
achieved. Washing with 1 M HCl removed the alkaloid and left the free acid, which
could be esterified to nicardipine following the formation of the acid chloride using
phosphorous pentachloride.82 This method has also been used in the synthesis of
barnidipine.83

Figure 2.2: Synthesis of (+) and (–)-nicardipine via alkaloid resolution
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In 1981 a group at Bayer reported the enantioselective synthesis of nimodipine using a
chiral auxiliary (Figure 2.3).84 The synthesis involved the Michael addition of (S)-2methoxy-2-phenylethyl 3-aminocrotonate 2.A with the condensation product of isopropyl
acetoacetate and 3-nitrobenzaldehyde 2.B. With this chiral auxiliary, the product formed
2.C was enantiomerically pure as the 4S isomer. Selective transesterification gave the
pure (S)-nimodipine.84

Figure 2.3: Stereoselective synthesis of nimodipine
Meyers and Oppenlaender reported in 1986 the use of a chiral oxazoline 2.D to induce
the diastereoselective addition of aryl lithium to a pyridine system, yielding a
diastereomeric excess (de) of 78-90% (Figure 2.4).85 The same system was used again in
1996, with Cheng et al. reporting that the aryl lithium preferentially added to the methyl
ester, which could be circumvented by using a tert-butyl ester 2.E.86 This addition
proceeded with a de of 67%.
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Figure 2.4: Diastereoselective formation of 4-aryl-1,4-dihydropyridines using a chiral
oxazoline
In 1988, D. Enders et al. reported an enantioselective synthesis of 4-aryl-1,4dihydropyridines using chiral hydrazines (Figure 2.5).87 An asymmetric Michael addition
of metalated chiral alkyl acetoacetate hydrazones 2.F to Knoevenagel acceptors 2.G and
subsequent cleavage of the nitrogen-nitrogen bond resulted in products with enantiomeric
excess (ee) between 84% and 98%.
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Figure 2.5: Stereoselective synthesis of 4-aryl-1,4-dihydropyridines using chiral
hydrazines
Lipases from Pseudomonas were shown in 1991 to selectively cleave one of two ester
groups of a symmetrical 1,4-dihydropyridine, providing an enantiomerically pure product
(2.H, Figure 2.6).88

Figure 2.6: Selective ester cleavage of symmetrical 1,4-dihydropyridine using
Pseudomonas lipase
Initial reactions were carried out in buffer at a pH of 5 giving the best ee of 15%.
Utilizing an n-butanol and water mixture in a ten to one ratio without buffer resulted in an
optimal ee of 97% in 31% yield. A higher yield was obtained by a shorter reaction time
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with a loss of enantiomeric excess. The side product of this reaction is the di-acid and the
yield for this compound increased over time.
In 1994 Kosugi et al. reported the synthesis of optically pure 1,4-dihydropyridine
derivatives via the diastereomeric separation of Hantzsch intermediates containing an
(R)-1-phenylethylamino group (Figure 2.7).89 Similar to what Enders reported in 1988,
Michael addition followed by the removal of the chiral auxiliary and cyclization gave the
desired 4-aryl-1,4-dihydropyridine (2.I).

Figure 2.7: Synthesis of chiral 4-aryl-1,4-dihydropyridines via diastereomeric
intermediates
The resolution of 4-aryl-1,4-dihydropyridine derivatives bearing isothioureido groups off
the 2-methyl was described in 2006 by Moshtaghi et al. (Figure 2.8).90 Bromination of
the methyl group followed by substitution with the thiourea resulted in the racemic
product that was resolved using dibenzoyl-tartaric acid.
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Figure 2.8: Synthesis of a chiral 4-aryl-1,4-dihydropyridine using tartaric acid resolution
The use of chiral BINOL-phosphoric acid catalysts was reported by Evans and Gestwicki
in 2009 resulting in up to >99% ee in 4-phenyl polyhydroquinoline derivatives (2.J,
Figure 2.9).91 The cyclohexa-1,3-dione dimedone (2.K) was used with ethyl acetoacetate,
ammonium acetate and various benzaldehydes in the presence of 10 mol% of catalyst in
acetonitrile at room temperature to give a selection of substituted 4-aryl-1,4dihydropyridine derivatives in at least 87% ee.

Figure 2.9: Use of chiral BINOL-phosphoric acid in the enantioselective synthesis of 4phenyl polyhydroquinolines
Although a few methods exist for enantioselective synthesis of a 1,4-dihydropyridine
system, chiral auxiliaries or chiral chromatography remain a mainstay in the syntheses of
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these molecules.85-89,

91-92

Polyhydroquinolines that are formed via the Hantzsch

dihyropyridine synthesis generally have only one stereocenter. Thus, a technique
allowing for the stereoselective synthesis of 1,4-dihydropyridine derivatives with a
second stereocenter would be a novel endeavor.
2.1.2

Biological Activity of 1,4-Dihydropyridine Derivatives

1,4-Dihydropyridines have long been known to have biological activity with the first
observed activities being analgesic and muscle-relaxing properties.93 In the early 1970’s
1,4-dihydropyridines were found to be calcium channel blockers (Figure 2.10).

Figure 2.10: Calcium channel blockers on the market
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These calcium antagonists reduce the influx of Ca2+ in the cells of the contractile system
resulting in the direct damping of myocardial work-load metabolism, an increase in blood
supply to the coronary vessels and a reduction in arterial flow resistance.84 The reduction
of arterial flow resistance has made these compounds effective drugs in the treatment of
hypertension and angina pectoris. The enantiomers of these compounds have been found
to have opposite effects, with one being an agonist and one being an antagonist. 85, 92a, 94 If
racemic mixtures are used, one enantiomer should be more active than the other.
Sirisha et al. have shown 1,4-dihydropyridine derivatives that display in vitro anti-cancer,
anti-bacterial and anti-tubercular activities (Figure 2.11, 2.L, 2.M and 2.N).95 Anti-cancer
activities for the most active compounds (2.L and 2.M) were on par with methotrexate in
the single digit g/mL range against cancer cells from breast (MCF-7), colorectal (HT29) and skin (A431) cell lines. For compound (2.N), anti-tubercular activity was reported
at 12.5 g/mL. Zones of inhibition against both gram positive and negative bacteria were
also reported for this compound. Mehta and Verma have also shown 1,4dihydropyridines with zones of inhibition against both gram positive and negative
bacteria.96
1,4-Dihydropyridines have also been found to have anti-inflammatory properties via the
inhibition of PDE4 enzymes,97 multidrug resistance reversal properties in anti-cancer
drugs via the inhibition of P-glycoprotein98 and have even shown single digit micromolar
activity in in vitro anti-leishmanial and anti-trypanosomal assays.99
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Figure 2.11: 1,4-Dihydropyridines recently reported with anti-cancer, anti-tubercular and
anti-bacterial properties
2.2

1,4-Dihydropyridine Syntheses

In 2010 a major high-throughput screening (HTS) was undertaken at St. Jude Children’s
Research Hospital.100 This screen started with 309,474 unique compounds tested at 7 M
against the 3D7 strain of Plasmodium falciparum. Approximately 1300 compounds
displayed >80% activity with 561 having EC50s less than 2 M and a selectivity index of
greater than ten when compared against two mammalian cell lines. Forty percent of these
compounds were re-purchased and tested and 172 were re-confirmed by three separate
laboratories to have anti-malarial activity.
In early 2012, the groups from St. Jude Children’s Research Hospital, Novartis and
GlaxoSmithKline published a review with results from independent anti-malarial HTS
screenings.101 In an attempt to involve more research groups in the search for novel antimalarials, these results were published with the hope that drugs would become available
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to further progress the elimination of malaria. As part of this testing, 4arylpolyhydroquinoline derivatives of asymmetric 1,4-dihydropyridines were identified
as hits and it was decided that we would begin work on this chemotype.
The synthesis of the 1,4-dihydropyridine derivatives began with 1,4,5,6,7,8hexahydroquinolines 2.O that were monosubstituted with phenyl derivatives at carbons 4
and 7 (Figure 2.12). This substitution pattern leads to compounds with two stereocenters,
with the formation of four stereoisomers. The presence of four stereoisomers required the
identification of which stereoisomer is biologically active. The stereoselective synthesis
of each stereoisomer was also investigated. Finally, a detailed structure-activity
relationship (SAR) was envisioned to identify the most potent derivatives in combination
with the most active stereoisomers.
2.2.1

Synthetic Plan

Chiral auxiliaries were used in order to add a preset chirality center to the molecules. It
was believed that the formation of four diastereomers would facilitate a straightforward
separation, allowing for the testing and crystallization of pure stereoisomers. Alongside
this, it was thought that the six position methylene could be replaced with an oxygen,
allowing for the formation of 1,4-dihydropyridine derivatives with structures of 4,5,7,8tetrahydro-1H-pyrano[4,3-b]pyridines 2.P (Figure 2.12). These derivatives could be
formed from 6-phenyldihydro-2H-pyran-2,4(3H)-diones 2.Q, lactones that could
potentially have chirality built in. The designed usage of the lactone for chiral synthesis
led to the idea of utilizing a lactone library for the SAR. While the chiral syntheses were
taking place, a racemic library would also be synthesized to determine the most active
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compounds. The methylene and oxygen derivatives would have to be compared to
determine if there was a loss or gain of activity between the two.

Figure 2.12: Retroysynthesis of 1,4-dihydropyridine derivatives
2.2.1.1 Comparison of Methylene and Oxygen Derivatives
The replacement of a methylene with an oxygen could potentially create drastic changes
between molecules. These isosteres have electronic differences that can play a significant
role in solubility, molecular interactions and lipophilicity, among other properties. In the
case of the 1,4-dihydropyridines, the syntheses of the two 6-position derivatives occurs
via the same route. Ethyl acetoacetate, benzaldehyde, ammonium acetate and either 5phenylcyclohexan-1,3-dione 2.R or 6-phenyldihydro-2H-pyran-2,4(3H)-dione 2.Q can be
heated at 120ºC in acetonitrile within a sealed tube. Cyclization gives the asymmetric 1,4dihydropyridine as the major product (Figure 2.13). The diastereomers of 1,4,5,6,7,8hexahydroquinolines 2.O and 4,5,7,8-tetrahydro-1H-pyrano[4,3-b]pyridines 2.P can be
separated via chromatography, with the derivatives of 2.P being more polar and more
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easily separated via traditional flash chromatography. The 2.O derivatives were not
readily separable by flash chromatography, but can be separated using preparative highpressure liquid chromatography (prep-HPLC). This ease of separability in the oxygen
derivatives was a bonus for the use of these derivatives in the SAR. The diastereomeric
pairs are labeled A and B, with A being the pair that moves more slowly on normal-phase
silica and more quickly on reverse-phase silica. Crystal structure of 2.1 revealed that 2.1A is the 4,7-cis isomer and that 2.1-B is the 4,7-trans isomer (Figure 2.27). The crystal
structure can also be used to explain why the trans isomer is formed in a slightly larger
amount, as an edge-face interaction can be seen between the 4- and 7- aryl substituents.
This interaction would lead to steric hindrance that results in the higher production of the
trans stereoisomers.

Figure 2.13: Synthesis of 1,4-dihydropyridine derivatives
Initial 1,4-dihydropyridines utilized a 4-(2-chlorophenyl) and 7-(3,4-dimethoxyphenyl)
substituent pattern. Comparison of the anti-malarial properties reveals that the activities
are generally diminished when an oxygen replaces the methylene at the 6-position (Table
2.1). Comparison of the A diastereomeric pairs cis-2.1 and 2.2-A show that the
methylene version is between 7.9 and 14 times more active than the oxygen version
across the four tested strains. The B diastereomers trans-2.1 and 2.2-B are significantly
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more active than the A diastereomers cis-2.1 and 2.2-A with the methylene derivative
again more active, although the W2 parasite was affected similarly by the two
derivatives. The methylene version is between 1.2 and 19 times more active than the
oxygen version across the four tested strains.
Table 2.1: Comparison of the replacement of -CH2- with -O- at the 6-position

Compound

X

2.1

CH2

2.2

O

A/B

3D7
EC50 n

K1
EC50 n

W2
EC50 n

TM90-C2B
EC50 n

J774A.1
EC50 

cis
trans
mix
A
B
mix

165
13.5
17.1
2330
260
372

141
15.7
28
1390
244
323

53.2
40
99
418
48.8
66

128
4.9
24.3
1190
91.2
180

>20
>20
>20
>20
>20
>20

The P. falciparum strains 3D7 and K1were provided by the MR4 Unit of the American
Type Culture Collection (ATCC, Manassas, VA). Those two strains were the chloroquine
sensitive strain 3D7 and the chloroquine resistant strain K1. Asynchronous parasites were
maintained in culture based on the method of Trager.102

Parasites were grown in

presence of fresh group O-positive erythrocytes (Key Biologics, LLC, Memphis, TN) in
Petri dishes at a hematocrite of 4-6% in RPMI based media (RPMI 1640 supplemented
with 0.5% AlbuMAX II, 25 mM HEPES, 25 mM NaHCO3 (pH 7.3), 100 µg/mL
hypoxanthine, and 5 µg/mL gentamycin). Cultures were incubated at 37°C in a gas
mixture of 90% N2, 5% O2, 5% CO2. For EC50 determinations, 20 µL of RPMI 1640 with
5 µg/mL gentamycin were dispensed per well in an assay plate (Corning 384-well
mircotiter plate, clear bottom, tissue culture treated, catalog no. 8807BC). An amount of
40 nL of compound, previously serial diluted in a separate 384-well white polypropylene
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plate (Corning, catalog no. 8748BC), was dispensed to the assay plate by hydrodynamic
pin transfer (FP1S50H, V&P Scientific Pin Head) and then an amount of 20 µL of a
synchronized culture suspension (1% rings, 4% hematocrite) was added per well, thus
making a final hematocrite and parasitemia of 2% and 1%, respectively. Assay plates
were incubated for 72 h, and the parasitemia was determined by a method previously
described:103 Briefly, an amount of 10 µL of the following solution in PBS (10X Sybr
Green I, 0.5% v/v triton, 0.5 mg/ml saponin) was added per well. Assay plates were
shaken for 1 minute, incubated in the dark for 90 minutes, then read with the Envision
spectrophotomer at Ex/Em of 485/535 nm. IC50s were calculated with the robust
investigation of screening experiments (RISE) with four-parameter logistic equation.
All synthesized 1,4-dihydropyridines were routinely tested against the clinically relevant
multidrug resistant malarial strains W2 (chloroquine and pyrimethamine resistant) and
TM90-C2B (chloroquine, mefloquine, pyrimethamine, and atovaquone resistant). The
human malaria parasite P. falciparum has been grown in vitro in dilute human
erythrocytes in RPMI 1640 media containing 10% heat inactivated plasma.104
Concentration response data have been analyzed by a nonlinear regression logistic dose
response model, and the 50% inhibition for each compound against the individual strains
has been calculated as the effective concentrations (EC50). Generally, the 1,4dihydropyridines do not display signs of cytotoxicity at less than 20 μM, rendering
cytotoxicity indices (CI = EC50(J774)/EC50(TM90-C2B)) of 1000 or more for the most
active compounds. These results indicate that the 1,4-dihydropyridines are selective and
nontoxic agents.
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2.2.1.2 Synthetic Scheme with Chiral Auxiliaries
Initial synthetic strategy for isolation of pure stereoisomers occurred with compound 2.1
(SJ000025107, initial compound number from St. Jude Children’s Reseach Hospital100)
after the separation of the diastereomeric pairs, cis-2.1 and trans-2.1. The enantiomers
were thought to be separated by the transesterification of the ethyl ester with a chiral
auxiliary,

allowing for the separation of

the newly formed

diastereomers.

Transesterification back to the ethyl ester would allow for the isolation of all four pure
stereoisomers of 2.1.
Transesterification

was

first

attempted

using

(S)-1,2-isopropylideneglycerol

in

tetrahydrofuran (THF) at high temperature within a sealed tube (Figure 2.14). No reaction
occurred over five hours, so 16 equivalents of acetic acid were added in the hopes of
having an acid catalyzed reaction occur. Heating for an additional 15 hours resulted in no
reaction, with compound 2.1 remaining intact.

Figure 2.14: Transesterification attempt with (S)-1,2-isopropylideneglycerol
Next, hydrolysis to the acid was attempted using 2 equivalents of lithium hydroxide in
THF and water at 65ºC for 24 hours and separately with 10 equivalents of aqueous
hydrochloric acid in THF and water at 65ºC for 36 hours (Figure 2.15).105 Both hydrolysis
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attempts resulted in no reaction occurring, showing that the reactivity of the 3carboxylate carbon is reduced in this system.

Figure 2.15: Hydrolysis with acid or base
Hydrolysis of the ester was thought to occur more readily by the use of an ester group
that was more easily removed. tert-Butyl acetoacetate was used in place of ethyl
acetoacetate in a trial run to form the tert-butyl ester 2.3 (Figure 2.16). The stable tertbutyl carbocation was believed to be formed via the reaction with acid, leaving the free
carboxylic acid. Reaction with 15 equivalents of hydrochloric acid in water at 100ºC for 3
hours resulted in no reaction.

Figure 2.16: Hydrolysis of the tert-butyl ester 2.3
As formation of the carboxylic acid did not readily occur, treating the carboxylate as a
leaving group was the next option. (9H-fluoren-9-yl)methyl acetoacetate 2.4 was
synthesized and used in the formation of the fluorenylmethyl ester 2.5. Treatment of this
compound with 1.5 equivalents of 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) at room
temperature resulted in the β-elimination of 9-methylene-9H-fluorene and the release of
the acid 2.6. At long last the free carboxylic acid was formed.
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Figure 2.17: Synthesis of the 3-carboxylic acid via β-elimination
In order to derivatize the acid to form the chiral esters and amides, a carbodiimide
coupling was attempted using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI)
and

4-dimethylaminopyridine

(DMAP)

in

dichloromethane

(DCM)

or

dimethylformamide (DMF) to couple the acid with the primary alcohol (S)-1,2isopropylideneglycerol, the secondary amide (S)-4-benzyl-2-oxazolidinone or the
secondary alcohol (S)-mandelic acid (Figure 2.18).

Figure 2.18: Acid derivatization attempts
No reactions were observed so a Mitsunobu reaction was attempted with the same acid
2.6

and

primary

alcohol

with

diisopropyl

azodicarboxylate

(DIAD)

and

triphenylphosphine in THF, again with no reaction. Chlorination of the acid to the acyl
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chloride with thionyl chloride was ineffective, as reactions in DCM or DMF followed by
quenching with even the small primary alcohol methanol resulted in no formation of the
ester.82-83, 89, 106 As a final derivatization effort, we attempted to synthesize the anhydride
using an acid chloride. (S)-Mosher’s acid chloride was added to the acid in THF
following the addition of 1.2 equivalents of sodium hydride. A reaction did occur with
these conditions, although oxidation of the 1,4-dihydropyridine was believed to occur
with decomposition of the side chain carboxylate.
Synthesis then proceeded with the formation of chiral acetoacetate derivatives with the
idea that if a chiral auxiliary could not be added to the 1,4-dihydropyridine acid 2.6, it
may be possible to add it prior to the cyclization. Two chiral auxiliaries were employed: a
threonine derivative 2.7 and an oxazolidinone derivative 2.8 (Figure 2.19).

Figure 2.19: Synthesis of chiral auxiliary acetoacetates
These chiral auxiliary containing acetoactetates and their enantiomers were employed in
the cyclization to form diastereomeric sets of polyhydroquinolines and were utilized due
to literature reports describing transesterification possibilities and were incorporated into
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the acetoacetate portion of the molecule.107 The L-threonine derivative (2S,3R)-2.7 was
cyclized via the Hantszch reaction and formed three peaks (2R,3S)-2.9 by HPLC (Figure
2.20).107c These three peaks, 2.9-P1, 2.9-P2 and 2.9-P3, were separated using prep-HPLC
(RP18) with an isocratic system utilizing 55:45 acetonitrile to water and 0.05%
trifluoroacetic acid (TFA). A note to the reader, the stereochemistry changes between 2.7
and 2.9 due to a change in IUPAC numbering system of the threonine side chain.

Figure 2.20: Analytical RP18 HPLC trace of threonine diastereomers
After separation of the three peaks using preparative HPLC, analytical chiral HPLC using
a Lux column confirmed that each peak was a single isomer. NMR of each threonine
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derivative, however, gave a surprising twist to what was believed to be three different
compounds (Figure 2.21).

Figure 2.21: Carbon NMR of threonine derivative 2.9-P1 (top) and 2.9-P2 (bottom)
between 103 and 171 ppm
The NMR of 2.9-P1 and 2.9-P3 were similar to each other, but comparison with 2.9-P2
revealed that there were an abnormally large number of peaks present. This led to the
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conclusion that 2.9-P2 was a mixture of two diastereomers that could not be separated by
RP18 prep-HPLC. 2.9 was synthesized from both D- and L- threonine, resulting in either
(2S,3R)-2.9 or (2R,3S)-2.9.
An immediate concern was that upon transesterification the ethyl ester versions of 2.9-P1
and 2.9-P3 would reveal that they were enantiomers and that this method would not
allow for the separation of all four stereoisomers. Luckily, transformation of 2.9-P2 to the
ethyl ester 2.1 resulted in the formation of a pair of diastereomers that could be separated
by RP18 HPLC, showing that all four stereoisomers were indeed formed and could be
separated (Figure 2.22).

Figure 2.22: Synthesis of pure 1,4-dihydropyridine stereoisomers via (2S,3R)-2.9-P2
Formation of the ethyl ester 2.1 from the threonine ester 2.9 occurred via two steps. First,
a β-elimination with DBU removed the threonine portion, leaving the free carboxylic acid
2.6. Next, the acid was reacted with ethyl iodide and potassium carbonate to give the
ethyl ester 2.1.
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X-ray crystallography is an excellent technique for determination of crystal packing
structure of molecules and also for the identification of stereochemistry of unknown
stereocenters. In order for this technique to be used, crystals of an adequate size and
quality need to be grown. As identification of the unknown stereochemistry of the 2.1
derivatives was a high priority, crystallization with ethanol, methanol, isopropanol,
DCM, DMF, acetonitrile, toluene and acetone was attempted via evaporation of solvent.
Unfortunately, using these conditions no crystals of 2.1, 2.9-P1 or 2.9-P3 could be
formed.
A second chiral acetoacetate was used for the preparation of diastereomeric 1,4dihydropyridines. The oxazolidinone 2.8 also cyclized via the Hantszch reaction and
formed three peaks by HPLC (Figure 2.23).

Figure 2.23: Synthesis of pure 2.1 stereoisomers via the chiral oxazolidinone side chain
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These three 2.10 peaks were separated using RP18 prep-HPLC under isocratic conditions
with 1:1 acetonitrile to water and 0.05% trifluoroacetic acid (TFA) (Figure 2.24). These
three 2.10 peaks correlated to three of the possible stereoisomers, unlike 2.9 where one of
the peaks consisted of two diastereomers. NMR of each 2.10 peak revealed each peak as
one isomer.

Figure 2.24: Analytical RP18 HPLC trace of oxazolidinone diastereomers
Formation of the ethyl ester 2.1 occurred at 150ºC in a sealed tube with ethanol and
titanium (IV) ethoxide with a poor yield of 28% (Figure 2.20).107a, b This esterification
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was attempted without the addition of the lewis acid with no reaction occurring,
indicating that the strongly acidic nature of the titanium (IV) is necessary for any reaction
to proceed. The poor reaction with the strong lewis acid again underlines the poor
reactivity of the 3-carboxylate of this 1,4-dihydropyridine system.
The use of both oxazolidinone enantiomers, (R)-2.8 and (S)-2.8, ensured the formation of
all four 2.1 stereoisomers. Each 2.8 enantiomer results in the cis compounds (4S,7S)-2.1
and (4R,7R)-2.1 and one trans-2.1. The oxazolidinone enantiomers (R)-2.8 and (S)-2.8
each react to form three respective diastereomers, (R)-2.10 and (S)-2.10 (Figure 2.25).

Figure 2.25: Formation of six 2.10 stereoisomers as three enantiomeric pairs
Analytical RP18 HPLC analysis of the ethyl esters 2.1 proved that 2.10-P1 and 2.10-P2
are 2.1-A enantiomers (Figure 2.26). 2.10-P3 corresponds to one 2.1-B enantiomer and is
formed in the lowest amount from 2.8, as seen by HPLC (Figure 2.24). Crystallization
with ethanol, methanol, isopropanol, DMF, acetonitrile, toluene and acetone was
attempted with 2.10 via evaporation of solvent. Although the alcohols, acetonitrile and
DMF all gave crystals, none were of a high enough quality for X-ray identification, thus
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vapor diffusion technique was implemented using dimethyl sulfoxide (DMSO) as the
solution solvent and an ethanol/water mix as the diffusion solvents.

Figure 2.26: Identification of 2.1 ethyl esters of 2.10-P1 and 2.10-P2 as enantiomers
Using this technique a crystal of both (R)-2.10-P1 and (S)-2.10-P1 were formed and Xray crystallography allowed the assignation of absolute stereochemistry for the 2.1-A
enantiomers. The 2.1-A 1,4-dihydropyridines are cis dihydropyridines and (R)-2.10-P1
had (4S,7S) stereochemistry while (S)-2.10-P1 had (4R,7R) stereochemistry. The crystal
structure of 2.10-P1 had two independent conformations in the crystal lattice (Figure
2.27). The 4-aryl substituent resides in a pseudoaxial conformation with the 7-aryl being
either axial or equatorial.
Analytical RP18 HPLC using a chiral Lux column allowed for the comparison of 2.1-A
enantiomers formed from 2.10 with the 2.1-A enantiomers from 2.9. This method proved
that 2.1-A from (2S,3R)-2.9-P2 has (4S,7S) stereochemistry and 2.1-A from (2R,3S)-2.9-
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P2 has (4R,7R) stereochemistry, the same as (R)-2.10-P1 and (S)-2.10-P1, respectively
(Figure 2.28).

Figure 2.27: Crystal structure of (R)-2.10-P1 with equatorial 7-substituent (top) and axial
7-substituent (bottom)
Utilizing these two chiral auxiliaries, we were able to determine the absolute
configuration of the 2.1-A enantiomers, determine the relative stereochemistry of the 2.1B enantiomers as trans conformers and isolate all four stereoisomers of 2.1 in pure form.
The use of the 2.7 threonine derivative provided a higher yielding method than the use of
the 2.8 oxazolidinone derivative (Table 2.2).
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Figure 2.28: Synthesis of (4S,7S)-2.1-A from (2S,3R)-2.9-P2 and (R)-2.10-P1
While the synthesis requires three more steps, a 27.4% overall yield was obtained
compared to a 10.5% yield with the oxazolidinone. Separation using the preparative
HPLC also occurred more easily with the threonine derivative, all four stereoisomers are
formed with the use of one auxiliary enantiomer and more than 50% of the product
formed is the more active 4,7-trans conformer. Crystal structures were found using 2.8,
but in all other ways 2.7 was the better auxiliary.
Table 2.2: Comparison of oxazolidinone and threonine auxiliaries
Cost of auxiliary (Sigma)
Number of Steps
Total Yield
Stereoisomers formed
Prep-HPLC Separation
Amount of B

Oxazolidinone
(R) - $117/5 g – (S) - $95/5 g
3
10.5%
3
Peak overlap
<25% of total

Threonine
L - $22/10 g – D - $33/5 g
6
27.4%
4
No overlap
>50% of total

2.2.1.3 Synthetic Schemes for Chiral β-Ketolactones
The reasoning behind the use of the lactone was the setting of one stereocenter prior to
formation of the 1,4-dihydropyridine core. If the stereochemistry of the 7-position could
be set, isolation of pure stereoisomers would depend solely on separation of two
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diastereomers. As shown in Table 2.1, the replacement of a methylene with an oxygen at
the 6-position reduced the activity significantly. It was believed that the easier formation
of pure stereoisomers would make up for the reduced activity and the performed SAR
would at the least lead to more active compounds that could be reevaluated with the
methylene unit.
Synthesis of the racemic lactone 2.11 began with the formation of the dianion of ethyl
acetoacetate prepared from the consecutive additions of sodium hydride and n-butyl
lithium to the acetoacetate in THF between -20 and 0ºC (Figure 2.27). This was followed
by the addition of a benzaldehyde derivative, yielding the secondary benzyl alcohol 2.12.
This alcohol was cyclized with KOH or p-toluenesulfonic acid (pTSA) to yield the βketolactone 2.11.108

Figure 2.29: Example of the formation of a β-ketolactone from a benzaldehyde
With a usable synthesis for the racemic lactone 2.11, our efforts turned toward finding a
highly stereoselective synthesis of a chiral lactone. The idea was that if the benzyl
alcohol 2.12 could be formed with high enantioselectivity then the cyclization would
yield the chiral lactone.
Initial efforts began using the Mukaiyama aldol route using Chan’s diene 2.13, the ditrimethylsilyl (TMS) protected methyl acetoacetate. Addition of Chan’s diene to the
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aldehyde in the presence of (R)-BINOL with lithium chloride and titanium (IV)
isopropoxide yielded the TMS protected benzyl alcohol (Figure 2.28).109 Deprotection of
the TMS group with pyridinium para-toluenesulfonate (PPTS) resulted in a low
conversion. Optical rotation of the isolated alcohol 2.14 showed a low enantiomeric
excess (ee) when compared with the reported literature value.

Figure 2.30: Mukaiyama aldol route using Chan’s diene

Keck allylation was attempted using allyltributylstannane, (R)-BINOL and titanium (IV)
isopropoxide with 3,4-dimethoxybenzaldehyde in dichloromethane (DCM) with
molecular sieves at -20ºC (Figure 2.29).110 After 4 days, less than 20% yield was obtained
with 98% ee. Mitsunobu reaction was attempted to determine if one Keck allylation could
yield both enantiomers, but the reduction of ee to 20% rendered that idea obsolete. A
more electron deficient benzaldehye was used with the hopes of enhancing the
nucleophilic attack on the aldehyde. Keck allylation of 4-bromobenzaldehyde to form
2.15 followed by oxidative cleavage to the β-hydroxyaldehyde 2.16, C-H insertion using
ethyl diazoacetate and tin (II) chloride to form 2.17, cyclization to the β-ketolactone 2.18
and asymmetric Hantzsch reaction resulted in a 40% ee of 2.19 that was unacceptable. At
this point it was believed that the 2,6-lutidine was causing a drop in ee.
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Figure 2.31: Hantzsch reaction using a chiral lactone derivative 2.16
The next route began with an allylation using Brown’s reagent.111 This reaction
proceeded

at

-90ºC

in

diethyl

ether

with

the

addition

of

(+)-B-

allyldiisopinocampheylborane to the 3,4-dimethoxybenzaldehyde (Figure 2.30). After
thirty minutes a 75% yield and 99% ee was obtained and the compound proceeded
through the same steps as the Keck allyation product, minus the addition of lutidine. With
this reaction sequence, and especially in the oxidative cleavage step, many inseparable
impurities were formed. This led to cyclization with pTSA giving the styrene elimination
product 2.20 as the major product. When less pTSA was used the reaction was stagnant
and low yielding. At this point it was believed that protecting the benzyl alcohol 2.21
would help to increase the yield and allow for easier purification. With a tributylsilyl
(TBS) protecting group, the yield from the benzyl alcohol 2.21 to the β-ketoester 2.22
dramatically increased from 20% to 52%, even with the extra protection step involved.
The deprotection step was troublesome where the use of HCl, PPTS, HF or
tetrabutylammonium fluoride (TBAF) resulted in an unclean reaction, again yielding a
large amount of the elimination product 2.20 (Figure 2.30).
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Figure 2.32: Brown’s allylation steps using a TBS protected benzyl alcohol
Due to the large amounts of styrene elimination product 2.20 being formed, we decided
to add the β-ketone last in order to eliminate a source of conjugation with the alkene.
Cross metathesis using Grubb’s second generation catalyst of the benzyl alcohol 2.21
obtained from Brown’s allylation with ethyl acrylate provided a Michael acceptor 2.25
that could have an oxygen placed in the correct location for oxidation to the ketone
(Figure 2.31).112 Reaction with potassium tert-butoxide and benzaldehyde gave a sixmembered acetal 2.26 that was added to the Michael acceptor in the fashion hoped for.112
Using pTSA monohydrate in methanol, it was expected that the acetal would be
hydrolyzed to the diol and that the benzyl alcohol would lactonize to give the desired
lactone that could be oxidized to the β-ketolactone 2.11. In reality, the conditions gave a
methanol addition product 2.27 that eliminated the compound for further use.
Dichloromethane in the place of methanol resulted in a low conversion rate with the diol
as a minor product and no cyclization. The use of acetic acid and water in a four to one
ratio resulted in no reaction.
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Figure 2.33: Cross metathesis and Michael addition of the Brown allylation product
One more attempt using Brown’s allylation product involved a ring closing metathesis
(RCM). The benzyl alcohol product 2.21 was reacted with acryloyl chloride in DCM with
either triethylamine (TEA) or pyridine, giving a compound 2.28 that was primed for the
RCM (Figure 2.32). Using Grubb’s first generation catalyst, the six membered alkene
2.29 was formed, albeit in 82% ee when TEA was used in the previous step and 88% ee
when pyridine was used.113

Figure 2.34: Ring-closing metathesis route
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After multiple attempts to form the chiral lactone derivative, it was decided that the
benzyl position was not stable enough to maintain a stereocenter with high ee. As the
SAR was already well underway at this point, the racemic lactone syntheses would
continue in the attempts to find more active substituents for the 1,4-dihydropyridine.
Isolation of a pure stereoisomer could then proceed via a chiral auxiliary route.
2.2.2

Structure-Activity Relationship of 1,4-Dihydropyridines

2.2.2.1 Structure-Activity Relationship at 4- and 7-Positions
Synthetic manipulations of the 1,4-dihydropyridine began with ortho-, meta- and parasubstitutions of the 4-phenyl ring with chloro-, methyl- or methoxy- substituents to
determine the effect of electronics and sterics on activity. As can be seen by compounds
2.2B and 2.32-B, chloro and methyl substitutions at the ortho position result in
submicromolar activity, with the methyl derivative displaying better activity against the
3D7 and K1 strains and the chloro derivative displaying better activity against the W2
and TM90-C2B strains (Table 2.3). Submicromolar activity was not seen with any meta
substitutions. Substitution at the para position resulted in submicromolar activities with
chloro and methyl substituted compounds 2.31 and 2.34-B, with the para chloro
derivative having better activity across the board.
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Table 2.3: 4-phenyl modificationsa

Compound

X

R

2.1

CH2

2-Cl

2.2

O

2-Cl

2.30

O

3-Cl

2.31

O

4-Cl

2.32

O

2-CH3

2.33

O

3-CH3

2.34

O

4-CH3

2.35

O

2-OCH3

2.36

O

3-OCH3

2.37

O

4-OCH3

A/B
cis
trans
mix
A
B
mix
A
B
mix
A
B
mix
A
B
mix
A
B
mix
A
B
mix
A
B
mix
A
B
mix
A
B
mix

3D7
EC50 n
165
13.5
17.1
2330
260
372
>10000
>10000
>10000
769
47.6
91.8
1270
38.5
72.7
>10000
>10000
>10000
>10000
638
1250
>5600
2050
>5500
>10000
>10000
>10000
>10000
>10000
>10000

K1
EC50 n
141
15.7
28
1390
244
323
>10000
>10000
>10000
633
53.8
160
2050
59.7
123
>10000
>10000
>10000
>10000
605
1610
>5600
>5500
>5500
>10000
>10000
>10000
>10000
>10000
>10000

W2
EC50 n
53.2
40
99
418
48.8
66
3930
1640
2700
470
49.0
87.0
1720
56.9
144
3810
2640
4210
2500
230
534
>5000
732
1290
2980
2920
>5000
3150
1780
2400

TM90-C2B
EC50 n
128
4.9
24.3
1190
91.2
180
>5000
>5000
4330
822
65.6
102
4030
189
300
4070
>5000
>5000
4220
327
995
>5000
>5000
>5000
2710
2930
>5000
>5000
2710
3120

J774A.1
EC50 
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
n/d
n/d
n/d
>20
>20
>20
>20
>20
>20

a

Chloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, EC50TM90-C2B =
55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone (EC50W2 = 0.574 ± 0.306
ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 1.41 ± 0.29 ng/mL, EC50TM90-C2B =
1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-malarial activity assays. Podophyllotoxin is the
internal control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1.

Extended aromatic systems at the 4-position, including 2- and 3-naphthyl and 4-(4biphenyl) (Table 2.4, 2.40-2.42), decrease the activity of the 1,4-dihydropyridine system,
with no submicromolar activities. The 4-bromophenyl 2.38 fared better but was less
active than the 4-chlorophenyl 2.31. The 4-nitrophenyl 2.39-B has submicromolar
activity against W2 and TM90-C2B only.
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Table 2.4: Aromatic changes at 4-positiona

3D7
K1
W2
TM90-C2B
J774A.1
EC50 n
EC50 n
EC50 n
EC50 n
EC50 
A
1450
3370
2350
>5000
>20
4-bromophenyl
B
59
341
170
285
>20
2.38
mix
213
634
375
725
>20
A
>10000
>10000
2610
3000
>20
4-nitrophenyl
B
2710
2200
317
386
>20
2.39
mix
>10000
>10000
>5000
>5000
>20
A
>10000
>10000
2850
2130
>20
1-naphthyl
B
>10000
>10000
3180
3270
>20
2.40
mix
>10000
>10000
>5000
>5000
>20
A
>10000
>10000
4110
>5000
>20
2-naphthyl
B
>10000
>10000
3040
>5000
>20
2.41
mix
>10000
>10000
1620
>5000
>20
A
>10000
>10000
>5000
>5000
>20
4-(4-biphenyl)
B
>10000
>10000
1640
1990
>20
2.42
mix
>10000
>10000
2220
>5000
>20
a
Chloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, EC50TM90-C2B
= 55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone (EC50W2 = 0.574
± 0.306 ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 1.41 ± 0.29 ng/mL,
EC50TM90-C2B = 1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-malarial activity assays.
Podophyllotoxin is the internal control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against
J774A.1.
Compound

R

A/B

Next, the 7-phenyl ring was looked at synthetically with the same ortho-, meta- and parasubstitutions with chloro-, methyl- or methoxy- substituents. Substitution at the para
position resulted in one compound with submicromolar activity in the 3D7 and K1
assays, the chloro derivative 2.45-A (Table 2.5). The 2.45-B and 4-methoxy derivative
2.51-B gave single digit micromolar activity in these assays, with the 4-methyl derivative
2.48-B giving single digit micromolar activity against K1 only. Submicromolar activity
was seen in the W2 assay with the 4-methyl 2.48-B and the 4-methoxy 2.51-B. Single
digit micromolar activity in the TM90-C2B assay was found with these compounds. Meta
substitution again gave one compound with submicromolar activity in the 3D7 and K1
assays with single digit micromolar activity in the W2 and TM90-C2B assays, the
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methoxy derivative 2.50-B. The 2.50-A derivative had single digit micromolar activity
against the all strains besides K1. W2 was the only strain to show activity when ortho
substitution was present, with the o-methyl 2.46-B having submicromolar activity.
Table 2.5: 7-Phenyl moficationsa

Compound

R

A/B

3D7
EC50 n

K1
EC50 n

W2
EC50 n

TM90-C2B
EC50 n

J774A.1
EC50 

A
>5500
>5500
2250
>5000
n/d
B
>5500
>5500
>5000
>5000
n/d
mix
>6000
>6000
3070
>5000
n/d
A
>6000
>6000
>5000
>5000
n/d
3-Cl
B
>6000
>6000
2050
4030
n/d
2.44
mix
>6000
>6000
3260
4130
n/d
A
510
560
2060
2030
n/d
4-Cl
B
2860
2160
1150
4060
n/d
2.45
mix
>5500
>5500
1720
2260
n/d
A
>5000
>5000
4610
4370
n/d
2-CH3
B
>5000
>5000
711
4080
n/d
2.46
mix
>5000
>5000
4430
4130
n/d
A
>5000
>5000
>5000
>5000
n/d
3-CH3
B
>6000
>6000
2110
4350
n/d
2.47
mix
>5000
>5000
3250
>5000
n/d
A
>5000
>5000
>5000
>5000
n/d
4-CH3
B
>6000
1583
923
3310
n/d
2.48
mix
>5000
>5000
1870
>5000
n/d
A
>6000
>6000
>5000
>5000
n/d
2-OCH3
B
>5500
>5500
4050
3840
n/d
2.49
mix
>6000
>6000
4050
4240
n/d
A
2133
>7000
2260
2280
n/d
3-OCH3
B
626
363
1490
2260
n/d
2.50
mix
2417
>6000
2100
2650
n/d
A
>7000
>7000
4480
4240
n/d
4-OCH3
B
2155
1960
871
2730
n/d
2.51
mix
>7000
>7000
1670
3830
n/d
a
Chloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL,
EC50TM90-C2B = 55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone
(EC50W2 = 0.574 ± 0.306 ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 =
1.41 ± 0.29 ng/mL, EC50TM90-C2B = 1.76 ± 0.12 ng/mL) are the internal controls for the in vitro antimalarial activity assays. Podophyllotoxin is the internal control for the in vitro cytotoxicity assay with
EC50 = 250 ± 10 nM against J774A.1.
2.43

2-Cl

As can be seen by Tables 2.3 and 2.4, changes to the 4-aryl position can increase the
activity of the new compound or severely limit it. Phenyl substitution of 4-halo, 4-methyl,
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2-chloro or 2-methyl results in compounds with submicromolar activities, with the best
activities found with a 4-chloro or a 2-methyl, compounds 2.31-B and 2.32-B. Extended
aromatic systems such as naphthyl or biphenyl completely remove the activity from 3D7
or K1 and may display low micromolar activity in W2 and TM90-C2B.
Substitution of the 7-phenyl system also plays a distinct role on activity (Table 2.5). Most
of the mono-substituted compounds are inactive against 3D7 and K1, with the exceptions
of the 4-chloro 2.45-A and the 3-methoxy 2.50-B having submicromolar activities. The
same can be said for W2 and TM90-C2B, as no compounds displayed submicromolar
activity against TM90-C2B while the 2-methyl 2.46-B, 4-methyl 2.48-B and the 4methoxy 2.51-B had submicromolar activity against W2. Comparision of Table 2.4 with
compound 2.2 highlights the importance of a disubstituted phenyl substituent at the 7position.
2.2.2.2 Structure-Activity Relationship of the 2- and 3-Positions
To test the importance of the ester functional group, a number of derivatives were made
by varying the ester substituent at the 3-position. The benzyl ester 2.57 did not have good
activity (Table 2.6). A tert-butyl 2.56-B or n-propyl 2.55-B ester had similar activities
against K1, W2 and TM90-C2B, while the tert-butyl had no activity against the 3D7
strain. The ethyl ester (Table 2.2, 2.2-B) was more active than either ester. Changing the
group at C2 revealed that extending the chain increases the activity, with n-propyl 2.52-B
enhancing the activity against 3D7 and K1 while keeping in the range of the methyl
against W2 and TM90-C2B. Also, a 2-ethoxy-2-oxoethyl 2.53-B increased activity
against 3D7 and K1 with a mild decrease against W2 and TM90-C2B. The 2.53-A
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diastereomers have a much better activity against all four strains when compared to the
2.2-A diastereomers and has activity better than or the same as 2.53-B. A 2-methoxyethyl
group with a methyl ester 2.54-B had better activity against 3D7 and K1 and lower
activity against W2 and TM90-C2B compared to 2.2-B. Attempts to place a phenyl group
at the 2-position resulted in no 1,4-dihydropyridine formation, thus the activity for an
aromatic group could not be seen.
Table 2.6: 2- and 3-position modificationsa

Compound

R1

R2

2.52

Et

nPr

2.53

Et

2-ethoxy-2oxoethyl

2.54

Me

2-methoxy
ethyl

2.55

nPr

Me

2.56

tBu

Me

2.57

Bn

Me

A/B
A
B
mix
A
B
mix
A
B
mix
A
B
mix
A
B
mix
A
B
mix

3D7
EC50 n
811
16.1
29
38.1
119
58.7
2440
86.6
237
2360
458
1670
>13000
>13000
>13000
>11800
>9100
>7500

K1
EC50 n
418
9.2
15.5
13.6
77.6
22.2
>10000
124
315
>7000
332
1630
>13000
272
2650
>11800
>9100
>7500

W2
EC50 n
>5000
48.7
261
133
124
346
1690
180
432
2400
205
62.1
1230
302
510
>5000
3230
1070

TM90-C2B
EC50 n
>5000
114
718
312
346
671
4190
746
962
>5000
1370
1210
2810
950
2520
>5000
>5000
>5000

J774A.1
EC50 
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20

a

Chloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, EC50TM90-C2B =
55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone (EC50W2 = 0.574 ± 0.306
ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 1.41 ± 0.29 ng/mL, EC50TM90-C2B =
1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-malarial activity assays. Podophyllotoxin is the
internal control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1.

Changing of the alkyl substituent on the 3-position ester did not form a compound with
better activity than the original ethyl ester, 2.2. The benzyl ester had no activity while a
tert-butyl ester or n-propyl ester each showed submicromolar activities in three of the
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four assays (compounds 2.55-2.57). The ethyl ester is clearly a better compound than
these other three.
Substitution at the 2-position did, however, create some interesting compounds.
Elongation of the methyl 2.2 to a propyl 2.52 formed a compound with better activity in
half of the assays. Replacement with some oxygenated ethyl derivatives resulted in some
B compounds 2.53-B and 2.54-B with better activity in half of the assays and worse in
the other half, while the 2.53-A oxygenated ethyl derivative fared much better than the
methyl 2.2A.
2.2.2.3 A Few Polyhydroquinoline Derivatives
The synthesis of a 2-phenylpolyhydroquinoline derivative 2.58 allowed for biological
screening with a 2-aryl substituent. The activity of this molecule was less than that for the
methyl derivative, 2.1 (Table 2.7). The 4-(4-chlorophenyl) derivative 2.59-B was slightly
more active than the 2-chloro version 2.1-B in all assays except for the TM90-C2B,
where 2.1-B is 12 times more active. Replacing the 2-position methyl of 2.59-B with a 2ethoxyethyl 2.60-B creates a compound with better across the board activity.
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Table 2.7: Polyhydroquinoline derivatives with C2 and C4 changesa

3D7
K1
W2
TM90-C2B
J774A.1
EC50 n
EC50 n
EC50 n
EC50 n
EC50 
A
3720
>10900
2260
3990
>20
Et
phenyl 2-Cl
B
40.5
46.7
119
256
>20
2.58
mix
176
92.3
274
570
>20
A
264
221
284
511
>20
Et
methyl 4-Cl
B
10.3
9.3
27.3
60.8
>20
2.59
mix
16.3
18.9
70.4
103
>20
A
145
130
191
434
>20
2Me ethoxy 4-Cl
B
2.5
15
3.9
7.1
>20
2.60
ethyl
mix
6.3
11
29.4
20
>20
a
Chloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, EC50TM90-C2B = 55.5
± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone (EC50W2 = 0.574 ± 0.306
ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 1.41 ± 0.29 ng/mL, EC50TM90-C2B =
1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-malarial activity assays. Podophyllotoxin is the
internal control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1.
Compound

R1

R2

R3

A/B

2.2.2.4 Role of Stereochemistry in Activity
Pure stereoisomers of 2.1 were formed via the chiral auxiliaries. Table 2.1 already
showed that the trans isomer was more active. As seen in Table 2.8, stereochemistry
plays a large role in the activity of 1,4-dihydropyridines in P. falciparum. (-)-Trans-2.1
is completely inactive to all four strains while its enantiomer (+)-trans-2.1 has activity in
the picomolar range. The same trend is seen with the cis isomers. The (4R,7R)-2.1
enantiomer is inactive while the (4S,7S)-2.1 enantiomer has double digit nanomolar
activity against 3D7 and K1 and triple digit nanomolar activity against W2 and TM90C2B.
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Table 2.8: Comparison of activities of 2.1 stereoisomersa

3D7
K1
W2
TM90-C2B
J774A.1
4,7Stereochemistry
EC50 n
EC50 n
EC50 n
EC50 n
EC50 
4S,7S
>6000
>6000
2130
2110
n/d
2.1
4R,7R
17
10.5
200
514
n/d
2.1
(+)-trans
<0.3
<0.3
18.1
49.1
n/d
2.1
(-)-trans
>6000
>6000
>5000
>5000
n/d
2.1
a
Chloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL,
EC50TM90-C2B = 55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone
(EC50W2 = 0.574 ± 0.306 ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 =
1.41 ± 0.29 ng/mL, EC50TM90-C2B = 1.76 ± 0.12 ng/mL) are the internal controls for the in vitro antimalarial activity assays. Podophyllotoxin is the internal control for the in vitro cytotoxicity assay with
EC50 = 250 ± 10 nM against J774A.1.
Compound

2.2.2.5 Role of Stereochemistry on Solubility and Permeability
Solubility at pH 7.4 was determined using Biomek FX lab automation workstation with
pION µSOL evolution software as reported previously.114 Passive transcellular
permeability was assessed in a standard parallel artificial membrane permeability assay
(PAMPA) at pH 7.4. Solubilities of the four stereoisomers ranged from 0.2 µM for (+)trans-2.1 to 2.9 µM for (4S,7S)-2.1 (Table 2.9). Membrane permeabilities for all four
stereoisomers were in a suitable range.
Table 2.9: Comparison of solubilities and permeabilities of 2.1 stereoisomersa

Compound
2.1
2.1
2.1
2.1

4,7Stereochemistry
4R, 7R
4S, 7S
(+)-trans
(-)-trans

Solubility pH 7.4 µM
1.3
2.9
0.2
1.3

a

Permeability pH 7.4
Pe 106 cm/s
R%
1180 ± 130
80 ± 2
872 ± 105
85 ± 3
846 ± 102
86 ± 0
1110 ± 460
80 ± 4

Albendazole (2.4 ± 0.8 μM, 352 ± 35 cm/s, 2.4 ± 0.8%), carbamazepine (91.8 ± 1.2 μM, 111 ± 30
cm/s, 38 ± 4%), ranitidine HCl (81.1 ± 1.2 μM, 4 ± 1 cm/s, 4 ± 1%) and verapamil HCl (74.9 ± 1.7
μM, 1950 ± 240 cm/s, 59 ± 12%) are the internal controls for the solubility and permeability assays.
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2.3

Summary

Thirty-three 1,4-dihydropyridine diastereomeric pairs were synthesized and the structureactivity relationship studied. Twenty-nine of these derivatives contained a 6-position
oxygen, with 2.31, 2.32, 2.52 and 2.53 having single and double digit nanomolar
activities. This SAR study revealed some insightful information about the 1,4dihydropyridine substitution pattern (Figure 2.35). A few combinations would be
interesting to synthesize to see how the activities combine. At the 4-position, a 4-chloro2-methylphenyl derivative could be expected to increase the activity. A 4-chloro-3methoxyphenyl at the 7-position can be tested to see how it compares with the 3,4dimethoxyphenyl substituent.

Figure 2.35: Anti-malarial SAR of the 1,4-dihydropyridine
Using the SAR from the 6-position oxygen derivatives, 6-methylene derivatives with 4(4-chlorophenyl) 2.59 and 2.60 were synthesized that displayed better activity than the
original 4-(2-chlorophenyl) 2.1 derivative.
Lastly, stereochemistry was revealed to play an important role in the activity of 2.1. One
stereoisomer, (+)-trans-2.1, had subnanomolar activity. Another stereoisomer, (4S,7S)2.1, had nanomolar activity. The other two stereoisomers were inactive.
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1,4-Dihydropyridines have been shown to have potential in the treatment of malaria. The
performed SAR has given incredible insight for this chemotype. The high selectivity of
these compounds between P. falciparum and human cells is an encouragement for their
continued study. Based on the activities of the previous compounds it is recommended
that in vivo studies are begun to study the efficacy of these compounds in mammals.
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Chapter 3: Quinazolines as Anti-Leishmanials
3.1

Chemistry of the Quinazoline Class

Quinazolines are a class of compounds characterized by two fused six membered
aromatic rings, a benzene and a pyrimidine. The electronics of the quinazoline system
have two large dipoles, with increased electron density on the two nitrogens and electron
deficiency on the 2- and 4-carbons (Figure 3.1).115

Figure 3.1: Electronics of the quinazoline system
Electronically, the quinazoline nitrogens act like electron-withdrawing nitro groups. This
electron deficient property causes an activation of reactivity for halo-substituted
quinazolines 3.A when the halogen is at the 2- or 4-position, causing nucleophilic
aromatic substitutions to occur readily (Figure 3.2).115-116

Figure 3.2: Reactivity of the 2,4-dichloroquinazoline
The halogen at position 4 is more reactive than at position 2, allowing for reactions such
as aminolysis to occur under minimal conditions at the 4-positon 3.B and then the 273

position 3.C with more vigorous conditions.115-116 Substitution of the 4-halogen with an
amine again reduces the activity at the 2-position, as an electron-donating group is now
directly attached to the system.
3.2

Medicinal Importance of the Quinazoline Class

The quinazoline class of compounds displays a wide range of biological activity. They
have been shown in literature to have properties as anti-cancer, sedative-hypnotic, alpha
blocker, anti-fungal, anti-inflammatory, anti-convulsant, anti-malarial, anti-mutagenic,
anti-coccidial, anti-leukemic, CNS depressant, anti-leishmanial and anti-bacterial agents
(Figure 3.3).117 Pandeya et al. showed moderate anti-bacterial and anti-fungal activity
with Schiff bases of isatin containing quinazolinone derivatives.118 They tested the antiHIV properties of the compounds as well but did not find activity lower than the
cytotoxicity ceiling. Gawad et al. tested 3-arylquinazolin-4(3H)-ones in a growth
inhibition test against tumor cell lines and displayed results up to 80% inhibition of
growth at 10 M.119 Fluorinated hydroquinazoline derivatives were reported by Ghorab
et al. displaying anti-fungal activity with minimum inhibitory concentrations as low as 40
g/mL against Aspergillus ochraceus, Penicillium chrysogenum, A. flavus and Candida
albicans.120 Aly et al. reported 3-arylquinazolin-4(3H)-ones displaying anti-convulsant,
analgesic, anti-fungal against Fuzarium species yet no anti-bacterial activity.121 2Styrlquinazolin-4(3H)-ones displayed up to 88% growth inhibition of L-1210 cell lines at
1 g/mL in an anti-leukemic assay reported by Raffa et al.122 Werbel and Degnan
reported the reduction of in vivo malarial and in vitro leukemia cell activity with amine
substitution of quinazolin-2,4-diamine derivatives.123 Febrifugine derivatives were found
to have anti-coccidial activity in an in vivo chicken assay reported by Ye et al., with
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protection at 9 mg/kg.124 Kumar et al. tested mice and male albino rats for the antiinflammatory, analgesic and ulcerogenic activity of 2,3,6-trisubstitutedquinazolinones.125
The in vivo properties were thought to be favorable with subcutaneous or intraperitoneal
injections up to 100 mg/kg. Balakumar et al. showed imidazo[1,2-c]quinazoline
derivatives with anti-inflammatory activity in the same range as indomethacin, a standard
used for in vivo studies.126 Sedative-hypnotic and CNS depressant activities were reported
by Jatav et al. in in vivo screens of rats and mice with 3-thiadiazol-2-styrylquinazolin4(3H)-one derivatives.127 Doxazosin is a quinazolin-2,4-diamine -adrenoreceptor
blocker that is sold by Pfizer to treat hypertension.128As shown in the previous studies,
numerous in vivo studies have been conducted with quinazoline derivatives.

Figure 3.3: Biological role of quinazolines in the literature
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3.2.1

Quinazolines in the Literature as Anti-Leishmanials

Due to increased parasite resistance, cytotoxicity issues of current treatments, and long
treatment regimens, new drugs are necessary to have an effective strategy for treating
visceral leishmaniasis. Quinazolines are a class of compounds that have been studied and
have shown potential as anti-leishmanials. Berman et al. reported a class of 2,4diaminoquinazolines 3.D with ED50 as low as 0.04 nM against L. major amastigotes in
human monocyte-derived macrophages, however the development of this compound
series was abandoned due to toxicity issues (Figure 3.4).129 Bhattacharjee et al. 3.E, Ram
et al. 3.F, and Shakya and Gupta et al. 3.G and 3.H have also recently tested quinazolines
as anti-leishmanials with activities below 100 ng/mL in some cases.130 This class of
compound has been reported as being dihydrofolate reductase inhibitors, although
another mechanism of action may be involved with Leishmania.129, 131

Figure 3.4: Quinazolines shown to have anti-leishmanial activity
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3.3

Anti-Leishmanial Testing

Recently, we tested a small library of structurally diverse compounds, originally designed
as potential anti-cancer probes, for anti-leishmanial activity in a L. mexicana axenic
amastigote assay. Among this library were N2,N4-disubstituted quinazolines 3.1 and 3.2,
which are structurally different from quinazoline series A-E. Anti-leishmanial testing of
quinazolines 3.1 and 3.2 against L. mexicana axenic amastigotes revealed EC50 values in
the single digit micromolar range, motivating us to investigate whether quinazolines
structurally related to the hits 3.1 and 3.2 have potential to display potent anti-leishmanial
activity (Figure 3.5). Herein, we report a detailed structure-activity relationship (SAR)
study focusing on the 2-position, the 4-position, and the quinazoline’s benzenoid ring. All
compounds were initially examined in a L. donovani and L. amazonensis intracellular
amastigote assay to preselect quinazoline candidates. Promising compounds have
subsequently been tested for efficacy in a murine model of visceral leishmaniasis.

Figure 3.5: Hit compounds 1 & 2 and SAR positions of quinazoline
3.3.1

Synthetic Chemistry

The compounds were synthesized following known procedures (Figure 3.6).132
Commercially available anthranilic acids 3.I were cyclized with urea and the resulting
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quinazoline-2,4-dione 3.J was reacted with phosphorous oxychloride to give the 2,4dichloroquinazoline 3.K. Substitution with amines occurred selectively at position 4
yielding 4-amino-2-chloroquinazoline 3.L followed by substitution at position 2 to give
the 2,4-diaminosubstituted quinazoline 3.M. In this synthetic sequence, only 4-amino-2chloroquinazoline 3.L and the final N2,N4-disubstituted quinazoline-2,4-diamine 3.M
have been purified and characterized.

Figure 3.6: Synthesis of N2,N4-disubstituted quinazoline-2,4-diamines
3.3.2

In vitro Anti-Leishmanial Efficacy and Cytotoxicity

All target compounds were tested against L. donovani and L. amazonensis intracellular
amastigotes to identify molecules that are broadly active against these medically
important Leishmania species. The testing involved murine peritoneal macrophages as
host cells, since compounds with potential for clinical use must be able to penetrate the
infected macrophage in a human host. Anti-leishmanial activity was determined in an
assay using transgenic parasites expressing a β-lactamase gene as outlined previously.133
Concentration response data for each compound was fitted by a nonlinear regression
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model and the concentration that induces 50% inhibition was calculated as the effective
concentration EC50 (L. donovani or L. amazonensis.). Additionally, cytotoxicity against
the macrophage cell line J774A.1 was determined as the effective concentration EC50
(J774A.1) and the selectivity index SI was calculated as the ratio of EC50 value for
J774A.1 and the value for L. donovani (SI = EC50 (J774A.1)/EC50 (L. donovani)).
3.3.2.1 Structure-Activity Relationship Studies.
To validate and optimize the anti-leishmanial activity of N2,N4-disubstituted quinazoline2,4-diamines, two compound subseries were prepared and tested. The first subseries
focused mainly on the optimization of the N2- and N4-moieties (Table 3.1), whereas the
second subseries was designed to investigate whether analogues being substituted at the
quinazoline's benzenoid ring display improved anti-leishmanial activity (Table 3.2). In
vitro antileishmanial potency of compounds against intracellular L. donovani133b and L.
amazonensis132a parasites was measured using the colorimetric assay as described
previously.
Starting from hit compound 3.2, N4-furfuryl-analogues 3.3 and 3.4 were prepared in
which the N2-iso-propyl group was replaced by a short trifluoroalkyl- or hydroxyalkylgroup. While the 2,2,2-trifluoroethyl-substituted quinazoline 3.3 was slightly less potent
than compound 3.2, alcohol 3.4 lost potency against L. donovani and L. amazonensis by a
factor of 10 and >13, respectively. Testing of a small set of quinazoline-2,4-diamines 3.53.9 with N4-monosubstituted or N4-disubstituted with alkyl groups differing in size and
polarity did not identify a particular structural motif improving the potency over 3.2.
Replacement of the furfuryl and iso-propyl groups in 3.2 by two benzyl or two n-butyl
groups yielded quinazolines 3.10 and 3.11, of which both analogues were more potent
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than reference 3.2. Bis-benzyl-substituted quinazoline 3.10 displayed EC50s of 667 nM
against L. donovani and 1.41 μM against L. amazonensis, whereas analogue 3.11 was
approximately twofold less potent in comparison to compound 3.10. Consequently, a
following set of six quinazolines 3.12-3.17 was designed in which one of the 2- and 4positions was substituted by one benzyl amine, while the remaining position was
derivatized with an aniline, n-butylamine, or methylamine. Interestingly, with the
exception of the N4-benzyl-N2-methyl-quinazoline-2,4-diamine 3.12, all of these
compounds demonstrated sub-micromolar EC50s against L. donovani. Among these six
quinazolines tested, the N2-benzyl-quinazoline-2,4-diamines 3.15-3.17 appeared to be at
least twofold more potent against L. donovani than the N4-benzyl counterparts 3.12-3.14
suggesting that an N2-benzyl is more favorable than an N4-benzyl for anti-leishmanial
activity. This observation is similar to previous results with quinazolines 3.2-3.11.
Compound 3.15 was the most potent compound with an EC50 of 149 nM against L.
donovani. For L. amazonensis, the set of 3.12-3.17 displayed a similar activity trend, with
N2-benzyl-quinazolines 3.15 and 3.16 being the most potent compounds with
submicromolar or single digit micromolar EC50s.

80

Table 3.1: SAR study focusing on 2- and 4-positionsa

EC50 

L. amazonensis
EC50 

EC50 

SI

3.2

2.5 ± 0.4

3.7 ± 1.6

17 ± 6

6.8

3.3

3.6 ± 1.1

5.8 ± 2.3

23 ± 10

6.4

3.4

25 ± 18

> 50

> 33

> 1.3

3.5

3.7 ± 0.3

7.6 ± 3.2

> 33

> 8.9

3.6

4.3 ± 1.2

5.1 ± 0.9

20 ± 6

4.7

3.7

6.9 ± 1.8

20 ± 3

> 33

4.8

3.8

>50.0

> 50.0

n.d.

n.d.

3.9

8.9 ± 1.0

19 ± 3

> 33

> 3.7

3.10

0.67 ± 0.27

1.4 ± 0.5

5.5 ± 1.4

8.2

3.11

1.8 ± 0.4

2.1 ± 1.1

5.4 ± 1.4

3.0

3.12

1.5 ± 0.5

13 ± 3

18 ± 8

12

3.13

0.65 ± 0.10

1.8 ± 0.2

5.1 ± 1.5

7.8

3.14

0.64 ± 0.10

2.6 ± 0.7

6.8 ± 0.2

11

3.15

0.15 ± 0.02

0.90 ± 0.27

15 ± 1

100

3.16

0.34 ± 0.12

1.4 ± 0.2

4.9 ± 1.3

14

3.17

0.26 ± 0.15

2.2 ± 0.3

5.2 ± 1.3

20

Compound

R1

R2

L. donovani

J774A.1

a

Amphotericin B is the internal control for the in vitro anti-leishmanial activity assay with EC50 = 40 ± 9
nM against L. donovani and EC50 = 89 ± 16 nM against L. amazonensis. Podophyllotoxin is the internal
control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1.

N4-Furfuryl-N2-iso-propyl-substituted quinazoline 3.2, with EC50s of 2.50 M against L.
donovani and 3.71 μM against L. amazonensis, was considered to be well suited as the
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key scaffold for a SAR study focusing on the benzenoid moiety of the quinazoline core.
In a systematic approach following the Topliss operational scheme, compound 3.2 was
mono-substituted with either a chlorine atom, a methyl group, or a methoxy group in the
5-, 6-, 7-, and 8-positions to probe the benzenoid ring for steric and electronic effects.134
Overall, substitution on the benzenoid ring provided compounds with EC50s in the single
digit micromolar or sub-micromolar range against L. donovani. Among the chlorosubstituted subseries, 5- and 6-substituted analogues 3.18 and 3.19 were less potent by a
factor of two or more compared to reference 3.2, while the 7- and 8-substituted
quinazolines 3.20 and 3.21 displayed an activity on par with compound 3.2. In contrast,
the majority of the methyl- and methoxy-substituted quinazolines demonstrated a modest
potency improvement over quinazoline 3.2. For the methoxy-substituted quinazolines,
potency increased according to substitutions in 8- < 7- < 5- ≈ 6-position, whereas a
potency dependence in the order of 8- ≈ 6- < 7- ≈ 5-positions was observed for the
methyl-substituted compounds. 7-Methoxy-quinazoline 3.28 with an EC50 of 740 nM
against L. donovani was the most potent analogue of the compound subseries substituted
at the benzenoid ring. In contrast, the testing of the benzenoid ring substituted
quinazolines against L. amazonensis gave insight into a SAR, which differed from the
one observed for L. donovani. 8-Methoxy-substituted quinazoline 3.29 was the only
analogue which was marginally more potent than reference compound 3.2, whereas all of
the other analogues were equally or less potent than quinazoline 3.2.
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Table 3.2: Benzenoid substitution

L. donovani

L. amazonensis

J774A.1

EC50 

EC50 

EC50 

SI

-H

2.5 ± 0.4

3.7 ± 1.6

17 ± 6

6.8

-H

-Cl

4.4 ± 1.3

18 ± 6

> 33

> 7.5

-H

-Cl

-H

9.0 ± 3.7

23 ± 5

>100

> 11

-H

-Cl

-H

-H

2.6 ± 1.9

25 ± 4

> 33

> 13

3.21

-Cl

-H

-H

-H

2.3 ± 0.6

12 ± 3

25 ± 3

11

3.22

-H

-H

-H

-CH3

4.2 ± 2.1

4.4 ± 1.9

> 33

> 7.9

3.23

-H

-H

-CH3

-H

0.83 ± 0.32

4.1 ± 1.2

> 33

> 40

3.24

-H

-CH3

-H

-H

4.7 ± 2.5

15 ± 6

> 33

> 7.0

3.25

-CH3

-H

-H

-H

0.95 ± 0.27

3.6 ± 1.5

20 ± 9

21

3.26

-H

-H

-H

-OCH3

3.2 ± 1.2

7.3 ± 2.5

30 ± 5

9.4

3.27

-H

-H

-OCH3

-H

1.2 ± 0.5

10 ± 2

16 ± 2

13

3.28

-H

-OCH3

-H

-H

0.74 ± 0.37

9.6 ± 3.0

14 ± 1

19

3.29

-OCH3

-H

-H

-H

0.97 ± 0.26

2.7 ± 1.4

18 ± 6

19

Compound

R1

R2

R3

R4

3.2

-H

-H

-H

3.18

-H

-H

3.19

-H

3.20

a

Amphotericin B is the internal control for the in vitro anti-leishmanial activity assay with EC50 = 40 ± 9 nM
against L. donovani and EC50 = 89 ± 16 nM against L. amazonensis. Podophyllotoxin is the internal control for
the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1.

3.3.2.2 Cytotoxicity
An important quality of the quinazolines is their selectivity to inhibit parasite growth over
mammalian cells. Generally, the majority of the quinazolines 3.2-3.29 exhibited EC50s of
20 μM or higher against J774A.1 (Tables 1 and 2). Quinazolines 3.18-3.20 and 3.22-3.24,
whose benzenoid ring is substituted with one chloride or one methyl in 5-, 6- or 7position, were significantly less toxic than their reference 3.2. The quinazolines
displaying potent anti-leishmanial activity, especially the N2-benzyl-quinazoline-2,4diamines 3.15-3.17, were shown to have respectable SI values of 10 and larger indicating
that they are relatively selective, nontoxic chemotypes. Toxicity of compounds against
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the murine macrophage cell line J774A.1 was conducted using the 3-(4,5)dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as previously
described135 except that cells were incubated with compounds for 72 h.
3.3.3

Mechanism of Action

We investigated the possibility that quinazolines inhibit folate metabolism in the parasite.
L. donovani axenic amastigotes and J774A.1 (mouse macrophage cell line) were adapted
to grow in media deficient in p-aminobenzoic acid (PABA) and folic acid prior to
susceptibility testing. Susceptibility to quinazolines, methotrexate, pyrimethamine, and
miltefosine were assessed in the presence or absence of folinic acid (Figure 3.7).

Figure 3.7: In vitro efficacy of quinazolines, methotrexate (MTX), pyrimethamine (PYR),
and miltefosine (MILT) for axenic amastigotes of Leishmania donovani in the absence or
presence of d,l-folinic acid (FNA)
The presence of folinic acid dramatically increased the EC50 values of each of the
quinazolines as well as the methotrexate and pyrimethamine. For example, quinazoline
3.23 was 6.4 fold less potent in the presence of 488 nM folinic acid than in completely
deficient media. Conversely, efficacy of miltefosine was not affected by addition of
folinic acid to the media. Interestingly, we saw no antagonism of activity of quinazolines
84

3.10, 3.12, 3.13, 3.15, 3.16 or 3.23 for the mammalian cell line (J774A.1) in the presence
of folinic acid. For example, the EC50 of quinazoline 3.10 was 84.8 ± 2.2 μM and 84.2 ±
2.8 μM in the presence or absence of 488 nM folinic acid, respectively. In contrast, the
efficacy of methotrexate and pyrimethamine were antagonized significantly by folinic
acid in J774A.1. These results are consistent with the hypothesis that the quinazolines
interfere with folate metabolism in L. donovani.
3.3.4

Structure-Property Relationship Studies.

In parallel to testing the compounds for anti-leishmanial activity in vitro, a structureproperty relationship (SPR) study focusing on log D, aqueous solubility, and permeability
has been conducted with all compounds to assess potential physicochemical liabilities
(Table 3.3). Log D3.0 and Log D7.4, the distribution coefficient between octanol and water
at pH 3.0 and pH 7.4, were experimentally determined via a previously described HPLCbased method.136 Solubility at pH 7.4 was determined using Biomek FX lab automation
workstation with pION µSOL evolution software as reported previously and at pH 2.0
using an in-house HPLC assay based on UV absorption.114 Passive transcellular
permeability was assessed in a standard parallel artificial membrane permeability assay
(PAMPA) at pH 7.4 and pH 4.0. Generally, the aqueous solubility, the distribution
coefficient Log D, and the permeability of all quinazolines display a pH dependence
(exemplified on Log D or permeability in Table 3.3). The permeability is enhanced at
neutral pH while the aqueous solubility and Log D are better at lower pH ranges.
However, since the aqueous solubility, the distribution coefficient, and the permeability
are within the acceptable ranges (solubility > 20 M, Pe > 10 x 10-6 cm·s-1, 1 < Log D <
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4), the quinazoline compound series is considered to be suitable for the development of
bioavailable anti-leishmanial compounds.
Table 3.3: Physicochemical properties of quinazolines
Compound
3.2
3.3
3.4
3.5
3.6
3.7
3.8
3.9
3.10
3.11
3.12
3.13
3.14
3.15
3.16
3.17
3.18
3.19
3.20
3.21
3.22
3.23
3.24
3.25
3.26
3.27
3.28
3.29

Solubilitya
pH 7.4
*****
***
****
*****
****
****
****
***
**
***
*****
***
*
***
***
*
**
****
****
***
****
****
****
***
****
****
*****
****

pH 2.0
*****
*****
*****
*****
*****
*****
*****
*****
****
*****
*****
*****
**
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****

Permeability Pe ·10-6
(cm/s)b
pH 7.4
pH 4.0
883
62.2
979
67.7
1130
26.4
780
19.7
1480
28.8
744
38.8
783
112
1120
72.3
383
312
880
485
n/d
n/d
1250
161
1480
271
1720
57.1
1020
341
663
412
1330
67.6
1380
103
1630
170
1240
169
666
45.9
798
67.2
789
67.2
812
45.9
1060
38.4
1330
59.2
1010
80.2
624
87.0

a

Log D
pH 7.4
3.15
4.20
2.19
3.19
3.02
2.54
4.69
3.13
3.82
3.89
3.14
3.80
4.17
2.96
3.84
4.25
3.96
3.91
3.99
4.44
3.55
3.61
3.63
3.55
3.40
3.70
3.58
3.35

pH 3.0
2.18
2.02
1.48
2.40
2.06
1.73
3.56
1.64
2.82
2.91
2.11
2.84
2.78
2.00
2.86
2.67
2.38
2.51
2.60
2.62
1.57
1.58
1.55
2.44
2.99
3.11
2.95
2.53

(*) for solubility ≤ 5 μM, (**) for 5 μM < solubility ≤ 10 μM, (***) for 10 μM < solubility ≤ 20 μM, (****) for
20 μM < solubility ≤ 30 μM, (*****) for solubility ≥ 30 μM. n/d: not determined. b For the determination of the
Pe values, the following internal controls were utilized: carbazepine pH 4.0 permeability Pe = 108·10 -6 (cm/s)
and pH 7.4 permeability Pe = 130·10-6 (cm/s); ranitidine·HCl pH 4.0 permeability Pe = 5.2·10-6 (cm/s) and pH
7.4 permeability Pe = 2.2·10-6 (cm/s); verapamil·HCl pH 4.0 permeability Pe = 20.6·10 -6 (cm/s) and pH 7.4
permeability Pe = 1360·10-6 (cm/s).
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3.3.5

In Vivo Anti-Leishmanial Efficacy Studies

For the selection of the candidates for in vivo efficacy against L. donovani, only
compounds which displayed submicromolar in vitro activity against L. donovani with a
SI value greater than ten and a balanced combination of good physicochemical properties
were chosen. Among the benzyl-substituted quinazolines 3.12-3.17,

3.15 and 3.16

appeared to be the best candidates for in vivo evaluation due to their combination of
potency, selectivity, and favorable physicochemical properties. From the compound
subseries substituted at the benzenoid ring, the physicochemical properties were not
discriminatory and hence compound 3.23 was chosen as a viable candidate due to its
submicromolar EC50 against L. donovani as well as the outstanding SI value of this
compound (> 40).
The three compounds mentioned above were dissolved in an appropriate vehicle (3.15
and 3.23 dissolved in 0.5% methyl cellulose and 0.1% Tween80 in water, 3.16 dissolved
in 45% (w/v) (2-hydroxypropyl)-β-cyclodextrin (HPβCD) solution) and administered to
uninfected BALB/c mice intraperitoneally to determine a tolerated dose for in vivo
efficacy studies. While 3.15 was well tolerated when given at 30 mg/kg ip for five
consecutive days, 3.16 (slowed breathing) and 3.23 (hypoactivity) were toxic to animals
when given at the same dosing regimen. Considering the toxicity of 3.16 and 3.23 when
given at 30 mg/kg i.p., lower doses of these compounds were administered in subsequent
in vivo efficacy studies in a murine visceral leishmaniasis model (Figure 3.8). When
tested at 5 × 15 mg/kg ip, 3.23 inhibited liver parasitemia by 37% compared to the
vehicle control. However, 3.15 did not show significant anti-leishmanial efficacy when
tested at 5 × 30 mg/kg i.p. There was also no significant difference in the parasite burden
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between mice in the group treated with compound 3.16 (5 × 10 mg/kg i.p.) and the
vehicle control group (P > 0.05). As expected, the 45% HPβCD vehicle used to solubilize
3.16 itself resulted in 18% inhibition of liver parasitemia, consistent with a previous
report.133b
The in vivo antileishmanial efficacy of compounds was evaluated in a murine model of
visceral leishmaniasis by the general method described earlier132a with minor
modifications. Briefly, BALB/c mice were inoculated with LV82 promastigotes on day 0,
and then weighed and marked individually on day 6 in order to calculate the volume of
solution to be administered to each mouse. In these studies, 45% (w/v) (2hydroxypropyl)-β-cyclodextrin (HPβCD) vehicle was used to formulate 3.16 and 0.5%
methyl cellulose/0.1% Tween80 in water (MC) was used to dissolve 3.15 and 3.23; all
compounds and vehicles were administered intraperitoneally. After 5 consecutive days of
treatment from days 7 to 11, animals were sacrificed on day 14. Liver smear slides from
each animal were made and stained, and the liver parasitemia expressed in LeishmanDonovan units (LDU) was determined by microscopy.132a The efficacy of each
compound was calculated according to the method published previously.132a
Results are presented as the liver parasitemia (LDU) for each mouse (♦) and the average
LDU in each group (-) determined by microscopy (n = 4). (A), LDU for mice treated with
3.16 and 3.23; (B), LDU for mice treated with 3.15. All treatments were given by the i.p.
route. Compounds 3.15 and 3.23 were dissolved in 0.5% methyl cellulose and 0.1%
Tween80 (MC), while compound 3.16 was dissolved in 45% (w/v) (2-hydroxypropyl)-βcyclodextrin solution (HPβCD). (*): p < 0.05, compared with untreated control.
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Figure 3.8: In vivo efficacy of quinazolines against LV82 in L. donovani infected
BALB/c mice.

89

3.3.6

Pharmacokinetics of 3.16 and 3.23

Pharmacokinetic studies were conducted to determine the systemic and target tissue
exposures of 3.16 and 3.23. The mean plasma and tissue concentration–time profiles of
3.16 and 3.23 after p.o. and i.p. administration are shown in Figure 3.9 and Figure 3.10,
respectively. The relevant pharmacokinetic outcomes are listed in Table 3.4. After p.o.
administration at 100 µmol/kg (or approximately 30 mg/kg), both compounds were
absorbed from the gastrointestinal tract of mice and plasma concentration reached a Cmax
of 0.44 and 0.25 μM for 3.16 and 3.23, respectively.

Figure 3.9: Plasma (open circles) and tissue (squares for liver and triangles for spleen)
concentration-time profiles after p.o. (A) and i.p. (B) administration of 16 in mice at a
dose level of 100 μmol/kg (~30 mg/kg)
Symbols and error bars in Figure 3.9 and Figure 3.10 represent the mean and standard
error of triplicate determinations, except those labeled with asterisks where only one or
two determinations were obtained due to sample loss. 3.23 was below the detection limit
(0.1 μM) in the liver and spleen 12 and 24 h after i.p. administration.
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The systemic and tissue exposure of 3.16 (AUC and Cmax) were considerably greater than
those of 3.23 (Table 3.4). After i.p. administration, plasma concentration reached a Cmax
of 5.2 and 2.7 μM for 3.16 and 3.23, respectively, before decreasing rapidly in the first 4
h, followed by a slower elimination process until 24 h. The rapid decline in plasma
concentration was likely due to extensive tissue redistribution after absorption, as
indicated by the high target tissue concentrations. The plasma and tissue exposures after
i.p. administration were markedly greater than those after p.o. administration (Table 3.4),
suggesting significant first-pass metabolism and/or partial gastrointestinal absorption
after oral administration of 3.16 and 3.23.
Table 3.4: Pharmacokinetic outcomes of 3.16 and 3.23 after p.o. and i.p. administration to
mice
p.o.
i.p.
Outcomes
plasma liver spleen
plasma liver spleen

16

Cmax

(μM)

0.44

15.8

7.0

5.21

148

163

Tmax

(h)

4

1

1

1

1

1

(μM•h)

7.8

110

68

11

500

620

(h)

NCb

NDc

ND

20

ND

ND

AUClasta
t1/2

23

Mic t1/2d

(min)

Cmax

(μM)

0.25

5.2

0.9

2.67

48

45.8

Tmax

(h)

1

1

1

1

1

1

(μM•h)

2.5

29

7.4

4.6

42

71

(h)

24

ND

ND

5.4

ND

ND

AUClasta
t1/2
Mic t1/2d

27

9.4

(min)

a

AUC(0-24h) was calculated for plasma using noncompartmental analysis, whereas AUC(1-24h) was calculated for
tissues using trapezoid rule. AUClast, AUC from the time of dose to the last measurable concentration; C max and Tmax,
maximum concentration and time to reach C max; t1/2, terminal half-life. b NC, not calculable due to lack of a data point.
c
ND, not determined. d In vitro mouse liver microsomeal half-life.
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The terminal elimination half-life ranged from 5 to 20 h. Minor reversible overt toxicity
(hypoactivity) was observed after i.p. administration of 3.16, however more severe
toxicity was observed, unexpectedly, after a single i.p. administration of 3.23, which
warranted euthanization of some mice within 15 min post dose. As efficacy was
evaluated at lower doses than 30 mg/kg to avoid toxicity and dose linearity for
pharmacokinetic outcomes were unknown, it is not possible to directly correlate drug
exposure with anti-leishmanial activity in mice. In addition, it is worth pointing out that
the terminal half-life of 3.23 after i.p. administration was considerably shorter than that
after p.o. administration (5 h vs. 20 h; Table 3.4), and the liver concentration of 3.23 was
detectable at 12 and 24 h after p.o. administration, whereas it was below detection limit
after

i.p.

administration

(Figure

3.10).

These

observations

suggest

flip-flop

pharmacokinetics, where the rate of gastrointestinal absorption is slower than the rate of
elimination due to dosage formulations (e.g. sustained-release), excipients, physicological
factors (e.g. intestinal mobility and pH), and/or drug characteristics.137 The dramatic
decrease (~12-fold) in the permeability of 3.23 from neutral to acidic pH (Table 3.3)
could contribute to the slowed absorption of this compound in the upper gastrointestinal
tract. In contrast, the permeability of 3.16 decreased only 3-fold from neutral to acidic pH
(Table 3.3). Furthermore, 3.23 was metabolized quickly in the mouse liver microsomes
(t1/2 = 9.4 min; Table 3.4), suggesting that it is possible that the rate of elimination was
greater than the rate of gastrointestinal absoption for 23.
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Figure 3.10: Plasma (open circles) and tissue (squares for liver and triangles for spleen)
concentration-time profiles after p.o. (A) and i.p. (B) administration of 23 in mice at a
dose level of 100 μmol/kg (~30 mg/kg)
3.3.7

Summary

N2,N4-disubstituted quinazoline-2,4-diamines 3.1 and 3.2 were found to display antileishmanial activity in the single digit micromolar range. Subsequently a total of 28
molecules have been synthesized systematically by varying the substitutions in the 2-, 4-,
5-, 6-, 7-, and/or 8-positions. All quinazolines have been tested with the aim to further
optimize hit compounds 3.1 and 3.2 and to conduct a detailed SAR study against L.
donovani and L. amazonensis. The most potent activities with EC50s in the
submicromolar range against L. donovani were obtained with quinazoline-2,4-diamine
scaffolds bearing either a N2-benzyl-N4-alkyl/phenyl or a N2-ispropyl-N4-furfuryl
substituent combination. Furthermore, although the benzenoid ring of the quinazoline2,4-diamine scaffold has been identified to play a secondary role for efficacy,
quinazolines substituted at the 5- or 6-position with one methyl or one methoxy group
have also been identified to possess submicromolar EC50s against L. donovani. The best
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quinazolines were shown to display cytotoxicity against the macrophage cell line
J774A.1 at 10 M or higher concentrations yielding SI values larger than 10. In addition,
assessment of key physicochemical properties confirmed that the quinazoline's aqueous
solubility, distribution coefficient, and passive transcellular permeability were in
acceptable ranges. These promising results led to efficacy testing of the lead compounds
3.15, 3.16 and 3.23 in an in vivo murine visceral leishmaniasis model. While compounds
3.15 and 3.16 did not have activity translate from in vitro to in vivo, quinazoline 3.23
reduced parasitemia by 37% when 15 mg/kg/day were given via the intraperitoneal route
for five consecutive days. Pharmocokinetic studies of compound 3.23 revealed a
maximum plasma concentration that was threefold higher than the EC50 and a terminal
half-life of 5 hours after i.p. administration. Thus, the observed potencies of frontrunner
compounds 3.15, 3.16 and 3.23 in conjunction with favorable physicochemical and
pharmacokinetic properties make N2,N4-disubstituted quinazoline-2,4-diamines a suitable
platform for the future development of anti-leishmanial agents.
3.4

Additional Testing

Following the initial study concluding with in vivo data showing a reduction of
parasitemia by 37%, a terminal half-life of 5 hours after i.p. administration and a plasma
Cmax 3.25 times the L. donovani EC50 for compound 3.23, an additional twenty-nine
compounds were synthesized with the hopes of improving the in vivo efficacy. These
compounds mostly carried aromatic N2- and/or N4- substituents as these were the
substituents that showed the highest activity in the previous study. A small sampling of
N2,N4 dialkyl substitutions were also included to see if a broader sampling would show
activity.
94

3.4.1

Structure-Activity Relationships

3.4.1.1 Structure-Activity Relationship of N2- or N4- Alkyl with N2- or N4- Alkyl/Aryl
As seen previously in Table 3.1, dialkyl substitution of the quinazolin-2,4-diamine
resulted in compounds with single digit micromolar activity against intracellular L.
donovani amastigotes (Table 3.5, compounds 3.30-3.35, 3.37). N4- phenyl or benzyl with
N2-isopropyl resulted in compounds 3.34 and 3.35 with activities at 2 M, while N4furfuryl-N2-methyl 3.36 lost all potency. Another N4-furfuryl compound, 3.38 with N2cyclopentyl, also lost all potency whereas the N2-cyclohexyl derivative displayed single
digit micromolar activity. The only compound from this set displaying submicromolar
activity was the N2-benzyl 3.41, the N4-isopropyl derivative of compound 3.15 from
Table 3.1. Replacing the N4-methyl of 3.15 with N4-isopropyl resulted in a drop of
activity from 150 nM to 380 nM, but the cytotoxicity stayed in the same range at 14 M.
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Table 3.5: N2- or N4- alkyl with N2- or N4- alkyl/aryl substitutions

L. donovani

J774A.1

EC50 

EC50 

3.30

6.3 ± 1.9

n/d

3.31

6.1 ± 2.8

n/d

3.32

2.2 ± 0.5

n/d

3.33

8.9 ± 0.1

n/d

3.34

1.9 ± 0.2

n/d

3.35

2.0 ± 0.1

n/d

3.36

>25

n/d

3.37

4.4 ± 1.2

n/d

3.38

>25

n/d

3.39

4.0 ± 2.5

n/d

3.40

12 ± 9

n/d

3.41

0.38 ± 0.09

14 ± 1

3.42

20 ± 5

n/d

3.43

11 ± 3

n/d

Compound

R1

R2

SI

37

3.4.1.2 Structure-Activity Relationship of N2,N4-Diaryl Derivatives
The diarylquinazolin-2,4-diamines generally had activity in the single digit micromolar
or triple digit nanomolar range, with the exception of the N2-furfuryl derivative 3.44
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(Table 3.6). Derivatives of compound 3.10 having benzyl substitutions at the para
position with chloro, methyl or methoxy at N2 and/or N4 had activities between 0.4 and 6
M with selectivity indexes around ten. The most active derivatives 3.46 and 43.7 were
substituted with N2-4-chlorobenzyl and N4-4-methylbenzyl respectively, with a benzyl on
the opposite amine. Compounds 3.49 and 3.52 were disubstituted with N2,N4-di(4methylbenzyl) and N2,N4-di(4-methoxybenzyl), respectively, and had potencies above 1
M.
Table 3.6: N2,N4-diaryl derivatives

L. donovani

J774A.1

EC50 

EC50 

3.44

14 ± 6

n/d

3.45

0.82 ± 0.23

8.4 ± 0.5

10

3.46

0.61 ± 0.12

5.8 ± 0.8

9.5

3.47

0.39 ± 0.16

4.8 ± 2.1

12

3.48

0.89 ± 0.10

6.9 ± 0.5

7.8

3.49

1.1 ± 0.5

n/d

3.50

2.5 ± 0.2

n/d

3.51

0.72 ± 0.10

6.8 ± 0.4

3.52

6.0 ± 2.9

n/d

Compound

R1

R2
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SI

9.4

3.4.1.3 Structure-Activity Relationship of N2,N4-Diaryl Derivatives with Backbone
Substitution
Derivatives of compound 3.15 were made with 6-methoxy, 6-chloro or 7-chloro
derivation (compounds 3.53-3.55, table 3.7). The 6-methoxy derivative, 3.53, was the
only compound of the three to have submicromolar activity, although with a modest
selectivity index of 14. Three 7-chloro derivatives of 3.10 were also made with all three
having activities less than 0.5 M (compounds 3.56-3.58). The trichloro 3.58 displayed
the highest potency at 260 nM with the monochloro 3.56 next with 370 nM and a
selectivity index of 38.
Table 3.7: 6- and 7-substituted derivatives

Compound

3.4.2

R1

R2

R3

L. donovani

J774A.1

EC50 

EC50 

SI
14

3.53

6-MeO

0.35 ± 0.06

4.8 ± 2.2

3.54

6-Cl

2.5 ± 0.3

n/d

3.55

7-Cl

1.4 ± 0.2

9.7 ± 4.0

6.9

3.56

7-Cl

0.37 ± 0.8

14 ± 1

38

3.57

7-Cl

0.26 ± 0.15

n/d

3.58

7-Cl

0.47 ± 0.05

5.1 ± 1.0

11

Structure-Property Relationship Studies

A structure-property relationship study was conducted for the new compounds as
described for the previous compounds (Table 3.8). As can be seen in the lower half of the
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table, the aryl substituted quinazolines have lower aqueous solubility and membrane
permeability.
Table 3.8: Physicochemical properties of quinazolines
Compound
3.30
3.31
3.32
3.33
3.34
3.35
3.36
3.37
3.38
3.39
3.40
3.41
3.42
3.43
3.44
3.45
3.46
3.47
3.48
3.49
3.50
3.51
3.52
3.53
3.54
3.55
3.56
3.57

Solubilitya
pH 7.4
***
***
***
****
****
****
****
***
****
****
****
****
***
***
**
n/d
*
****
*
*
*
*
*
n/d
n/d
n/d
*
*
*

Permeability Pe ·10-6
(cm/s)b
pH 7.4
pH 4.0
1490
13.6
1300
421
1190
42.1
744
38.8
1790
124
1340
159
744
4.51
1690
22.8
2090
116
854
176
788
46.1
436
71.1
963
10.5
543
n/d
288
72.2
n/d
n/d
n/d
n/d
854
67.3
1070
160
1
4
1350
246
1750
415
441
14.6
n/d
n/d
n/d
n/d
n/d
n/d
n/d
153
0.3
n/d
0.5
n/d

Log D
pH 7.4
2.45
3.04
3.14
n/d
3.62
3.50
2.61
2.88
3.54
4.18
4.66
3.54
2.59
3.23
3.25
n/d
n/d
n/d
n/d
n/d
n/d
n/d
n/d
n/d
n/d
n/d
n/d
n/d
n/d

3.58
(*) for solubility ≤ 5 μM, (**) for 5 μM < solubility ≤ 10 μM, (***) for 10 μM <
solubility ≤ 20 μM, (****) for 20 μM < solubility ≤ 30 μM, (*****) for solubility ≥
30 μM. n/d: not determined. b For the determination of the Pe values, the following
internal controls were utilized: carbazepine pH 4.0 permeability Pe = 108·10-6 (cm/s)
and pH 7.4 permeability Pe = 130·10-6 (cm/s); ranitidine·HCl pH 4.0 permeability
Pe = 5.2·10-6 (cm/s) and pH 7.4 permeability Pe = 2.2·10-6 (cm/s); verapamil·HCl
pH 4.0 permeability Pe = 20.6·10-6 (cm/s) and pH 7.4 permeability Pe = 1360·10-6
(cm/s).
a
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3.4.3

Pharmacokinetics of 3.41 and 3.46 After Intraperitoneal Administration in Mice

Pharmacokinetic studies were conducted to determine the systemic and target tissue
exposures of 3.41 and 3.46. The mean plasma and tissue concentration–time profiles of
3.41 and 3.46 after i.p. administration are shown in Figure 3.11.

Figure 3.11: Plasma and tissue concentration-time profiles after 10 mg/kg i.p.
administration of 3.41 and 3.46
The relevant pharmacokinetic outcomes are listed in Table 3.9. After i.p. administration,
plasma concentration reached a Cmax of 2.15 and 1.40 μM for 3.41 and 3.46, respectively.
The rapid decline in plasma concentration was likely due to extensive tissue
redistribution after absorption, as indicated by the high target tissue concentrations
(Figure 3.11). The tissue concentration of 3.41 drastically declined over 12 hours while
the decline was much slower for 3.46 with 10 μM concentrations still found at 12 hours
in the liver and spleen. The terminal elimination half-life was 2 hours and 9 hours for
3.41 and 3.46, respectively.
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Table 3.9: Pharmacokinetic outcomes of 3.41 and 3.46 after 10 mg/kg i.p. administration
to mice
i.p.
Outcomes
plasma
Cmax

(μM)

2.15

Tmax

(h)

0.25

AUClast

(μM•h)

7.14

t1/2

(h)

2.05

Cmax

(μM)

1.40

Tmax

(h)

0.50

AUClast

(μM•h)

15.7

t1/2

(h)

9.31

3.41

3.46

3.4.4

In Vivo Anti-Leishmanial Efficacy Studies of Compounds 3.28, 3.41 and 3.46

For the selection of the candidates for in vivo efficacy against L. donovani, only
compounds which displayed submicromolar in vitro activity against L. donovani were
chosen, with the rationale for selections based on other data we had acquired. Compound
3.28 was reintroduced because of its best-in-class activity among the original benzenoid
substitutions and excellent SPR data. Compound 3.41 was chosen as an analogue to 3.15.
It was believed that 3.15 lost all activity in the in vivo assay due to the presence of the N4methyl substitution and enzymatic demethylation in vivo. 3.41, with the N4-isopropyl
substitution, was hoped to circumvent this problem and maintain excellent activity in the
murine model. Compound 3.46, with admittedly poor SPR data, was chosen based on the
high concentration-time profiling found during the pharmacokinetic study.
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The three compounds 3.28, 3.41 and 3.46 were dissolved in a vehicle consisting of 5%
DMSO, 50% PEG 400, 10% ethanol and 35% water. When tested at 5 × 10 mg/kg ip,
3.28 inhibited liver parasitemia by 17%, 3.41 inhibited liver parasitemia by 24%, and
3.46 inhibited liver parasitemia by 12% compared to the vehicle control (Figure 3.12).

Leishman-Donovan Units (LDU)
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0
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Control
3.28
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3.46

Figure 3.12: In vivo efficacy of quinazolines in L. donovani infected BALB/c mice
3.4.5

Summary

Following the original study of 28 synthesized molecules with various substitutions in the
2-, 4-, 5-, 6-, 7-, and/or 8-positions, an additional 29 were synthesized and tested. The
most potent activities with EC50s in the submicromolar range against L. donovani were
obtained with quinazoline-2,4-diamine scaffolds bearing either a N2,N4-dibenzyl or a N2benzyl-6-methoxy-N4-methyl substituent combination. Enhancement of activity was
encountered with quinazolines substituted at the 7-position with a chloro group. The best
quinazolines were shown to display SI values larger than 10 with few compounds having
cytotoxicity values of 10 M or higher concentrations against the macrophage cell line
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J774A.1. These promising results led to efficacy testing of the lead compounds 3.28, 3.41
and 3.46 in an in vivo murine visceral leishmaniasis model. Of the three, quinazoline 3.41
reduced parasitemia the most by 24% when 10 mg/kg/day were given via the
intraperitoneal route for five consecutive days. Pharmocokinetic studies of compound
3.41 revealed a maximum plasma concentration that was 2.3 times higher than the EC50.
For compound 3.46, the concentration was 5.7 times higher than the EC50.
The observed potencies of frontrunner compounds 3.28, 3.41 and 3.46 in conjunction
with the earlier data from 3.15, 3.16 and 3.23 make N2,N4-disubstituted quinazoline-2,4diamines a possible platform for the future development of anti-leishmanial agents. In
vivo efficacy needs to be improved in order for a hit to become a lead and this may occur
via the study of new substituents. Complex secondary amines will be looked at as well as
some of the untested compounds from this study, such as 3.47, that have displayed decent
activities with better physicochemical properties.
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Chapter 4: Quinazolines and the ESKAPE Pathogens
4.1

Quinazolines as Anti-Bacterial Agents

Quinazolines are a class of compounds that have been studied and have shown potential
as anti-bacterial agents. Huband et al. have reported substituted quinazolin-2,4-dione 4.A
as bacterial gyrase and topoisomerase inhibitors (Figure 4.1).138 They report a minimum
inhibitory concentration against 90% of the tested strains (MIC90) of 0.5 µg/mL versus
staphylococci, 0.06 µg/mL versus streptococci, 2 µg/mL versus enterococci, and 0.5
µg/mL versus Moraxella catarrhalis, Haemophilus influenzae, Listeria monocytogenes,
Legionella pneumophila and Neisseria species. Compound 4.A was used in a S. aureus in
vivo murine acute lethal infection model, where an oral dose of 2.5 ± 1.8 mg/kg of 4.A
was found to protect 50% of mice infected with MRSA strain SA-1417.
Indolo[1,2-c]quinazoline 4.B and its analogues have been shown to have anti-bacterial
and anti-fungal activity by Rohini et al. (Figure 4.1).139 These compounds had zones of
inhibition (ZOI) in Kirby-Bauer tests, and their MICs were evaluated against Grampositive and negative bacteria, including Staphylococcus aureus, Bacillus subtilis,
Streptococcus pyogenes, Salmonella typhimurium, Escherichia coli and Klebsiella
pneumonia, and also against the fungi Aspergillus niger, Candida albicans and
Trichoderma viridae. 4.B had MICs between 2 and 5 µg/mL against all tested bacteria
and between 2 and 10 µg/mL for fungal isolates.
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Figure 4.1: Quinazolines with reported anti-bacterial activity
Mycobacterial growth inhibition and dihydrofolate reductase inhibition was reported by
DeGraw et al. with a series of 2,4-diaminoquinazolines 4.C (Figure 4.1).140 An MIC of
1.8 µM was reported for 4.C and a marked synergistic effect was found with
diaminodiphenyl sulfone. Although activity was found with Mycobacterium, 4.C was
found to be inactive against

Staphylococcus aureus, Enterococcus faecalis,

Corynebacterium acnes, Pseudominas aeruginosa, Erysipelothrix insidiosa, Escherichia
coli, Proteus vulgaris and Salmonella chloraesuis.
In vitro activity against E. coli, S. aureus and K. pneumonia was seen from 4.D at MICs
of 2 µM, 12 µM and 12 µM, respectively, as reported by Kung et al. (Figure 4.1).141 In an
in vivo murine model, 4.D afforded a 40% survival rate when injected subcutaneously at
100 mg/kg in mice infected with K. pneumonia.
Gottasová et al. reported the in vitro activity of 4-aniloquinazoline 4.E against B. subtilis
and S. aureus (Figure 4.1).142 An MIC of 10 µg/mL and an EC50 of 0.8 µg/mL for 4.E
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was found against S. aureus. 4.E also had an MIC of 1 µg/mL and an EC50 of 0.7 µg/mL
in assays using B. subtilis.
4.2

Quinazolin-2,4-Diamine Activity Against Methicillin-Reisistant Staphylococcus

aureus
Recently, we tested a small library of quinazolines, structurally different from previously
reported antibacterial quinazolines and originally designed as potential anti-leishmanials,
for anti-bacterial activity. The results were promising as several compounds had zones of
inhibition against methicillin-resistant Staphylococcus aureus (MRSA) in Kirby-Bauer
tests. The Kirby-Bauer test is an introductory assay that allows for the quick
identification of compounds that inhibit the growth of bacteria. A larger library was then
tested and minimum inhibitory concentrations (MICs) were determined for those
compounds having zones of inhibition. Herein, we report a detailed structure-activity
relationship (SAR) study focusing on the 2-position, the 4-position, and the quinazoline’s
benzenoid ring. Furthermore, we report the selection process leading to frontrunner
compounds displaying low mutation frequencies and promising in vivo efficacy in murine
models of infection.

Figure 4.2: Positions of the quinazoline ring
4.2.1

Testing of Quinazolines via Kirby-Bauer Assays

Assessment of the quinazolin-2,4-diamine structure shows three locales for substitution
patterns: N2-substitution, N4-substitution, and benzenoid substitution at positions C5-8
106

(Figure 4.2). Initial studies focused on the amine substitutions as shown in Table 4.1.
Based on Kirby-Bauer assays, zones of inhibitions were determined. S. aureus CBD-635
was struck out onto plates and incubated over night. A single colony was used to
inoculate broth and again allowed to grow overnight. The overnight culture was diluted
1:1000 into 5 mL of molten overlay agar and mixed, before being used to inoculate
growth plates. After plates were allowed to dry, 3 sterile filter disks were added per plate
and then inoculated with 10 µL of test compound. The stock concentration for each test
compound was 5 mg mL-1 suspended in DMSO. Bacterial plates were incubated for 24
hours and zones of inhibition (ZOI) were measured in millimeters, with the assay being
performed in triplicate.
First, a subset of N2,N4-substituted quinazolines were tested, in which N4 was modified by
a furfuryl moiety, while the N2-group was varied (Table 4.1). Quinazolines 4.1 and 4.2
with a N2-methyl or N2-ethyl did not have ZOIs in the Kirby-Bauer assays. Branched
alkyl groups on N2 furnished compounds 4.3 and 4.4 displaying inhibition while
unbranched polar substituents in 4.5 and 4.6 lacked any activity. Cycloalkyl groups on N2
varied in potency based on size: N2-cyclopropyl and N2-cyclobutyl quinazolines 4.7 and
4.8 were inactive while analogues 4.9 and 4.10 with a N2-cyclopentyl and a N2cyclohexyl respectively created ZOIs. Next, compounds were tested with a furfuryl group
at N2. Quinazoline 4.11 with N4-methyl was active while derivative 4.12 with a polar
alcohol functionality remained inactive. Conclusions from this set showed that when a
furfuryl was substituted at N4 activity would be seen when a bulky alkyl substituent was
at N2 while small substituents were tolerated at N4 with N2 furfuryl.
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A second subset of quinazolines was prepared to probe whether antibacterial activity can
be improved via steric and electronic effects on the quinazoline benzenoid ring (Table
4.2). N4-furfuryl-N2-isopropyl-substituted quinazoline 4.3 was selected as a reference
compound, to which analogues 4.13-4.24 were compared with mono-substitution at
positions C5-C8 with either a chloro, a methyl or a methoxy group. Quinazolines 4.134.16 with one chloro substitutent suppressed the growth of bacteria. The analogues 4.174.24 substituted with a methyl or a methoxy group were less potent with inhibition of
growth observed in 25% and 50% of the samples, respectively. The trend noted for this
set are that chloro- substitution is well tolerated while methoxy- is less so and methyl- is
even less.
With the idea to reduce the aromaticity, a subset of compounds was designed to test
whether N2- and N4-residues rich in sp3-hybridized carbons are tolerated without
compromising activity (Table 4.3). Analogues 4.25-4.40 were synthesized in which one
of the two N2,N4-substitutents was a methyl, an isopropyl, or a 2-hydroxyethyl group,
whereas the other consisted of a branched, an unbranched, or a saturated cycloalkyl
moiety. None of these analogues were particularly active with the exceptions of the N2cyclopentyl-N4-isopropyl derivative 4.32 and N4-cyclohexyl-N2-isopropyl derivative 4.38,
which both inhibited bacterial growth.

A final focus was compounds with aromatic substitution (Table 4.4). Analogues 4.414.54, bearing phenyl and/or benzyl derivation at N2 and/or N4 were successful in
inhibiting the growth of S. aureus in Kirby-Bauer tests.
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4.2.2

Minimum Inhibitory Concentration Assays

After the identification of active compounds by Kirby-Bauer testing, the minimum
inhibitory concentration (MIC) for these compounds was assessed to provide a more indepth structure-activity relationship. The minimum inhibitory concentrations (MIC) were
determined for compounds which displayed antimicrobial activity against S. aureus
CBD-635. Broth cultures were prepared as described above. These overnight cultures
were diluted 1:1000 into fresh media and 200 µL was transferred to a sterile 96-well
plate. Relevant concentrations of test compounds were applied to each well and samples
were mixed by pipetting before being incubated at 37°C overnight.

MICs were

determined by visual inspection for the minimum concentration of drug that produced no
bacterial growth (as determined by a lack of turbidity). The assay was performed in
triplicate to verify MICs.
The N2-isopropyl derivative 4.3 is more active than the N2-tert-butyl 4.4 derivative (Table
4.1). N2-cyclopentyl 4.9 and N2-cyclohexyl 4.10 display similar MICs and are
comparable to the isopropyl. N4-isopropyl derivative 4.12 had an MIC ten times lower
than the N4-methyl 4.11, with MICs of 35 and 390 , respectively.
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Table 4.1: SAR of N-alkyl-N-furfurylquinazolin-2,4-diames
ZOI
(mm)

MIC
(

Compound

ZOI
(mm)

MIC
(

4.1

none

n/d

4.7

none

n/d

4.2

none

n/d

4.8

none

n/d

4.3

10

177

4.9

12

162

4.4

9

337

4.10

10

155

4.5

none

n/d

4.11

10

393

4.6

none

n/d

4.12

12

35.4

Compound

Structure

Structure

C6-, C7- and C8- chloro substituted 4.13-4.15 had MICs 5-6 times more active than the
5-chloro 4.16 or unsubstituted benzenoid 4.3 (Table 4.2). The 8-methyl 4.17, the 5methoxy 4.24 and the 6-methoxy 4.23 were less active than the original unsubstituted
benzenoid compound.
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Table 4.2: SAR of benzenoid substitutions
ZOI
(mm)

MIC
(

Compound

ZOI
(mm)

MIC
(

4.3

10

177

4.19

none

n/d

4.13

10

31.6

4.20

none

n/d

4.14

12

31.6

4.21

none

n/d

4.15

11

31.6

4.22

none

n/d

4.16

9

158

4.23

10

240

4.17

10

337

4.24

9

320

4.18

none

n/d

Compound

Structure

Structure

The two lone active non-aromatic 2,4-diaminoquinazolines displayed quite different
MICs. The N2-cyclopentyl-N4-isopropyl 4.32 had an MIC comparable to the N4-furfurylN2-cycloalkyl 4.9 and 4.10 or N4-furfuryl-N2-isopropyl 4.3. Compound 4.38, N4cyclohexyl-N2-isopropylquinazolin-2,4-diamine with an MIC of 3.5 µM, was the only
analogue of the entire series displaying single digit micromolar activity. This lone highly
active dialkyl 2,4-diaminoquinazoline makes for an interesting point in the table.
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Table 4.3: N2- and N4-substitutions rich in sp3 hybridized carbons
ZOI
(mm)

MIC
(

Compound

ZOI
(mm)

MIC
(

4.25

none

n/d

4.33

none

n/d

4.26

none

n/d

4.34

none

n/d

4.27

none

n/d

4.35

none

n/d

4.28

none

n/d

4.36

none

n/d

4.29

none

n/d

4.37

none

n/d

4.30

none

n/d

4.38

13

3.52

4.31

none

n/d

4.39

none

n/d

4.32

8

185

4.40

none

n/d

Compound

Structure

Structure

N2-benzyl substituted 4.41 and 4.42 mimic the N2-furfuryl substituted quinazolines 4.11
and 4.12 (Table 4.4). N4-benzyl 4.47 displays a better activity than N4-furfuryl 4.53,
however, with respective MICs of 5.9 and 30 . Phenyl and benzyl substituted 4.484.50 have a wide range of MICs, from 30 to 1300 . N-butyl derivatives of N-benzyl
4.43 and 4.45 and N-phenyl 4.44 and 4.46 have MICs ranging from 6.5 to 160  with
N4-benzyl-N2-butyl 4.45 having an MIC of 6.5 .
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Table 4.4: N2- and/or N4-benzyl and/or phenyl substitutions
ZOI
(mm)

MIC
(

Compound

ZOI
(mm)

MIC
(

4.41

11

189

4.48

10

32.0

4.42

13

34

4.49

10

1300

4.43

12

163

4.50

10

30.6

4.44

12

34.2

4.51

10

28.5

4.45

12

6.53

4.52

10

28.5

4.46

14

34.2

4.53

11

30.3

4.47

13

5.88

Compound

4.2.3

Structure

Structure

Derivatization Based on Initial SAR

The three most active quinazolines found in the SAR were 4.38, 4.45 and 4.47.
Compound 4.38 was the lone highly active quinazoline without an aromatic side chain. It
was decided that analogues would not be synthesized based on mutation frequency, data
shown later (section 4.2.7). As seen in Table 4.4, all tested compounds with aromatic side
chains were active. Table 4.2 allowed for the determination that benzenoid chloro
substitution could increase the activity of new derivatives. Thus, analogues were
synthesized by combining the benzenoid 7-chloro group with a variety of N2- and N4benzyl substitutions and also by using para substituted benzyl amines.
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In comparison to reference compounds 4.45 and 4.47, 7-chloro-quinazolines 4.54 and
4.55 displayed slightly reduced MICs (Table 4.5).
Table 4.5: Combination with 7-chloro or p-substituted benzyl at N2 and/or N4
MIC
(

Compound

4.45

6.53

4.59

5.64

4.47

5.88

4.60

70.5

4.54

5.34

4.61

5.43

4.55

2.93

4.62

5.40

4.56

5.34

4.63

67.5

4.57

5.34

4.64

35.0

4.58

0.61

Compound

Structure

Structure

MIC
(

The para positions of the N2- and N4-benzyl moieties were considered to be ideal sites to
introduce chloro, methyl and methoxy groups. Mono N2-4-chlorobenzyl 4.56, N2-4methylbenzyl 4.59 and N2-4-methoxybenzyl 4.62, as well as the mono N4-4-chlorobenzyl
4.57, were as active as the parent 4.47. The mono N4-4-methylbenzyl 4.60 and N4-4methoxybenzyl 4.63 were less active than 4.47. The N2,N4-di-(4-methylbenzyl) 4.61 was
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as active as 4.47, N2,N4-di-(4-methoxybenzyl) 4.64 was less active, and N2,N4-di-(4chlorobenzyl) 4.58 was nearly ten times more active with an MIC of 0.61 .
The MIC of less than 1 µM for compound 4.58 was exciting and seen as a target to be
improved upon. Benzenoid chloro substitution was applied without success in
compounds 4.65 and 4.66 (Figure 4.6). A one hundred fold activity decrease from the
dichloro 4.58 to the trichloro 4.66 was observed. The N2-(p-methoxybenzyl) 4.62 was
also thought to be improved with 7-chloro substituted 4.65, but a four-fold drop in
activity

was

observed.

A

combination

7-chloro-N4-(p-chlorobenzyl)-N2-(p-

methoxybenzyl) 4.67 was tested and displayed better activity than the trichloro
compound, but was still not near the original activity that was hoped to be replicated.
Table 4.6: Combination with 7-chloro and/or p-substituted benzyl at N2 and/or N4
MIC
(

Compound

4.47

5.88

4.65

22.2

4.54

5.34

4.66

67.6

4.58

0.61

4.67

51.2

4.62

5.40

Compound

Structure
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Structure

MIC
(

4.2.4

Determination of Minimum Bactericidal Concentration for Compounds 4.47 and

4.58
An important distinction of antibiotics is whether they are bactericidal or bacteriostatic.
Bactericidal agents kill bacteria while bacteriostatic agents prevent their reproduction.
The minimum bactericidal concentrations (MBC) were determined from MIC samples.
The MIC samples were serial diluted and plated onto TSA plates. The plates were then
incubated overnight at 37°C. MBCs were determined by calculating the CFU per mL for
each of the concentrations of compounds tested. The data is represented as the percent
killing by comparing the drug containing samples to samples that contain no drug.
Quinazoline 4.47 was not found to be bactericidal when tested up to two and a half times
the MIC, with a percent recovery over 100% (Figure 4.3). 4.58, on the other hand, was
found to be bactericidal with a 95% recovery at four times the MIC and a percent
recovery of 1.0% at eight times the MIC. The MBC50 for 4.58 was 3.6 µM and was six
times the MIC at 0.61 µM.
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Figure 4.3: Percent recovery curves of 4.47 and 4.58
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4.2.5

Determining the Minimum Biofilm Eradication Concentration for Compound

4.47
Quinazoline 4.47 was also tested to determine the minimum biofilm eradication
concentration (MBEC). Determining the MBEC demonstrates if a compound is able to
target cells forming biofilms, which is a common problem in healthcare settings.
Quinazoline 4.47 was not found to eliminate biofilms when tested up to two and a half
times the MIC, with a percent survival over 100% (Figure 4.4).
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14

16

Concentration of 4.47 (M)

Figure 4.4: Percent survival curve for 4.47 against MRSA biofilm
The MBEC is determined based on the recovered CFU per milliliter compared to the
control with no added compound. Briefly, S. aureus biofilms were grown in a 96-well
plate, at 37°C for 24 hours. After this time, media was aspirated leaving a biofilm that is
adherent to the walls of the 96-well plate, and replaced with fresh media containing 0X,
0.2X, 0.5X, 1X, 2.5X, 5X or 10X the MIC of relevant compounds. Samples were
incubated at 37°C overnight, before gently being washed twice with sterile PBS, being
careful not to disrupt the biofilm. Buffer was then removed by aspirating and biofilms
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were disrupted by the addition of 200 μL of PBS and pipetting samples repeatedly until
all cells were in suspension. This was then serially diluted, and plated for viable colony
forming units. MBEC values were determined by comparison to untreated controls.
4.2.6

Cytotoxicity and Hemolysis Assays of Selected Compounds

The cytotoxicity of front runner compounds was determined against adenocarcinomic
human alveolar basal epithelial cells (A549 cells, Table 4.7). Front runner compounds
4.38, 4.45 and 4.47 had EC50s of approximately 20 µM against the A549 cells and
selectivity indices (EC50(A549)/MIC) between 3.0 and 6.3. The designed compound 4.58
had a selectivity index of 10 with a lower EC50 of 6.1 µM.
Table 4.7: A549 EC50 and selectivity indices of select compounds
Compound
4.38
4.45
4.47
4.58

EC50 (M)
22.2 ± 4.2
19.3 ± 2.6
25.6 ± 2.1
6.11 ± 1.47

SI (EC50/MIC)
6.3
3.0
4.4
10

As another cytotoxicity test, compound 4.47 was tested in a hemolysis assay to determine
the effect of this quinazoline against blood cells at the MIC. An optical density curve at
540 nm shows the free hemoglobin that is released from lysed cells. Over a four hour
period there was no significant difference between the standard solution with no
compound and the test solution with 4.47 at the minimum inhibition concentration
(Figure 4.5).
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Figure 4.5: OD540 of erythrocytes in the presence or absence of 4.47
4.2.7

Determination of Staphylococcus aureus Resistance to Quinazolines

An important attribute of potential anti-microbials is that spontaneous resistance is not
easily obtained. Spontaneous resistance occurs when point mutations results in the ability
of bacteria to gain resistance to antibiotics. Thus the spontaneous mutation frequencies
for a few of the frontrunner compounds were determined. Spontaneous mutation
frequencies were tested for compounds 4.38, 4.45 and 4.47 by plating 1 x 109 cells of S.
aureus CBD-635 on agar containing 2.5 X the MIC of each compound. For compound
4.38 a bacterial lawn was obtained, indicating that resistance to this compound was
encountered quite readily. Seven spontaneous mutants were found for bis-benzylsubstituted quinazoline 4.47 over ten replicates with a combined inoculum of 2.31 x 1010,
yielding a mutation frequency of 3.03 x 10-10. N2-butyl-N4-benzyl 4.45 grew no mutants
with a combined inoculum of 2.31 x 1010, resulting in a mutation frequency of less than 1
x 10-11. These results are very promising considering that generally a mutation frequency
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smaller than 10-8 is desired for the development of anti-bacterial agents. The seven
mutants formed using 4.47 were then tested against compounds 4.54-4.64.
4.47 lost all activity against the mutant strains, with MICs greater than 590 µM,
compared with 5.9 µM against the original USA 635 (Figure 4.6). 4.54, with an original
activity of 5.34 µM, had activity drop to 26 µM for M1 and M2 while it increased to 2.6
µM against M3-7. Activity for 4.55 was found to be 2.93 µM against the mutants and
original strain alike. Activity was reduced from 5.34 µM to 26 µM against M1 for 4.56,
while the activity against M2-M7 was increased to 2.6 µM. 4.57 saw the activity increase
from 5.34 µM to 2.6 µM against all seven mutants. 4.58 was only tested against M1 and
M2, and had activity drop from 0.61 µM to 24 µM. 4.59, with an original activity of 5.64
µM, had activity drop to 28 µM for M1 while it increased to 2.8 µM against M2-7.
Activity was reduced from 5.43 µM to 27 µM against M1 and M2 for 4.61, while the
activity against M3-M7 was increased to 2.7 µM. 4.62 had activity jump from 5.40 µM to
27 µM against M1-3 and to 270 µM against M4, while the activity increased to 2.7 µM in
M5-M7. In all mutant strains, 4.64 had a reduction of activity from 35 µM against the
original strain. Against strains M5 and M6 the activity was 125 µM and for the rest of the
strains it was greater than 250 µM. Compounds 4.60 (original MIC 70.5 ) and 4.63
(original MIC 67.5 ) were found to be more active against the mutants than the
original strain. Against M1 and M2 4.60 had MICs of 2.8 µM whereas the MIC for M3-7
was 28 µM. 4.63 had MICs of 2.7 µM in M4 and M6 and 27 µM in the rest of the
mutants. This data shows that although mutants are formed, they do not have broad
spectrum resistance to the class of quinazolines.
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Figure 4.6: MICs of selected compounds of against the seven mutants formed from 4.47
4.2.8

Exploring the Mechanism of Action for 4.45

DNA sequence analysis of the mutants formed from quinazoline analogue 4.45 was
employed to determine if a common mechanism of action could be determined from the
mechanism of resistance. The Quinolone Resistance-Determining Regions (QRDR) for
the genes encoding DNA gyrase (gyrA and gyrB) and topoisomerase IV (grlA and grlB)
were sequenced for the mutants and determined to be identical to the parent strain, using
the method reported previously by Horri et al.143 As quinazolines have been shown to be
inhibitors of dihydrofolate reductase (DHFR), sequencing analysis of the gene coding for
this enzyme was also undertaken.144 Again, the mutant strain was found to be identical to
the parent strain. These results allow for the conclusion that the mechanism of resistance
for the few mutant strains was not via a change in primary enzyme structure.
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4.2.9

Galleria mellonella Larval Model

Galleria mellonella larvae, also known as the wax moth, were used as an initial in vivo
model to determine efficacy of front runner compounds 4.38, 4.45, 4.47 and 4.58 (Figure
4.6). Uninfected larvae were injected with DMSO to determine the effect of the injection
solvent. Larvae were infected by injection with between 1.78 x 109 and 4.63 x 109 colony
forming units (CFUs) of S. aureus USA 300 FPR strain. One hour post-infection 5x or
10x the MIC for each compound was injected, or the larvae were left untreated.
30% of uninfected larvae died within twenty-four hours post DMSO injection while the
remaining 70% lived to day three (p = 0.057), p values were calculated using Graph pad.
Mortality was measured using a log rank and chi-square test with 1 degree of freedom.
The significance level was set at 0.05. All untreated infected larvae were dead within
forty-eight hours following infection. Compound 4.38 was tested at two inoculations,
2.89 x 109 and 4.63 x 109 CFUs (Figure 4.7). Within the first twenty-four hours, 50% and
20% of larvae died after doses of 4.38 of 5x and 10x the MIC, respectively, with 40%
from each surviving after day two from 2.89 x 109 CFUs. For 4.63 x 109 CFUs, 40% died
within twenty-four hours with 10% additional dying every twenty-four hours until day
three at a dose of 5x the MIC (p = 0.0526). At 10x the MIC, 30% died within twenty-four
hours and the remaining 70% survived until day three (p = 0.157).
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Figure 4.7: Wax worm larvae survival post-infection for 4.38 with low and high
inoculation volumes. Low and high refer to the inoculation volumes discussed earlier in
the text. * = p < 0.05
Quinazoline 4.45 was tested at two inoculations, 2.89 x 109 and 4.63 x 109 CFUs (Figure
4.8). In the 5x MIC test at 2.89 x 109 CFUs, 50% of larvae died within twenty-four hours
and 40% survived past day two (p = 0.156). 30% of larvae died within twenty-four hours
and the rest survived until day three in the 10x MIC test (p = 0.0268). For 4.63 x 109
CFUs, 80% died within twenty-four hours with 10% additional dying before day three at
5x the MIC (p = 0.156). At 10x the MIC, 40% died the first day, 10% the second and
30% the third (p = 0.0268).
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Figure 4.8: Wax worm larvae survival post-infection for 4.45 with low and high
inoculation volumes. Low and high refer to the inoculation volumes discussed earlier in
the text. * = p < 0.05
Compound 4.47 was tested at 1.78 x 109 CFUs (Figure 4.9). In the 5x MIC test, 10% of
larva died within twenty-four hours and an additional 40% died in the next twenty-four
hours, leaving 50% alive at day three (p = 0.0035). In contrast, 30% of larvae died within
twenty-four hours and an additional 40% died in the next twenty-four hours, leaving 30%
alive at day three in the 10x MIC test (p = 0.0573).
Compound 4.58 was tested at 2.89 x 109 CFUs (Figure 4.9). In the 5x MIC assay, 50% of
larvae died within twenty-four hours and the remaining 50% survived until day three (p =
0.0779). 30% of larvae died within twenty-four hours and an additional 10% died in the
next twenty-four hours, leaving 60% alive at day three in the 10x MIC test (p = 0.0147).
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Figure 4.9: Wax worm larvae survival post-infection for 4.47 and 4.58. * = p < 0.05
4.2.10 In vivo Efficacy Using a Murine Model of Lethal Peritonitis
The efficacy of compounds 4.45 and 4.47 were determined in a murine model of lethal S.
aureus peritonitis (Figure 4.10). Groups of six female 6 week old CD1 mice were
injected intraperitoneally with 1 x 108 CFUs of S. aureus USA 300. After one hour the
groups of mice were given intravenous injections with either 45% w/v (2hydroxypropyl)--cyclodextrin (HPCD) in water, 5 mg/kg or 10 mg/kg of vancomycin,
5x the MIC of 4.45 in 45% w/v HPCD in water and 1x, 5x, or 10x the MIC of 4.47 in
45% w/v HPCD in water. At 5 mg of vancomycin, three mice died after the first day
and the rest survived to the end of the week (p = 0.264). At 10 mg of vancomycin, one
mouse died after the first day and the rest survived to the end of the week (p = 0.027). For
compound 4.45, one mouse died immediately following the 5x MIC injection and the
other five survived to the end of the test at day 5 (p = 0.352). For compound 4.47, all six
mice survived 5 days at 1x the MIC (p = 0.0058) while one mouse died immediately
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following the 5x injection (p = 0.0589) and five died immediately following the 10x
injection. With injection of 45% w/v HPCD in water all six mice were dead by day
three (p = 0.53).
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10x 4.47

0
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Time (days)

Figure 4.10: Mice survival post-infection. * = p < 0.05
4.2.11 Conclusions
A total of 67 N2,N4-disubstituted quinazoline-2,4-diamines, many displaying antibacterial activities, have been synthesized systematically by varying the substitutions in
the 2-, 4-, 5-, 6-, 7-, and/or 8-positions. The most potent in vitro activities with MICs in
the single digit to sub-micromolar range against S. aureus were obtained with
quinazoline-2,4-diamines 4.38, 4.45, 4.47, 4.54-4.59 and 4.61-4.62 bearing a N4cyclohexyl-N2-isopropyl or N4-benzyl and either N2-benzyl or N2-n-butyl substituent
combination. Furthermore, the benzenoid ring of the quinazoline-2,4-diamine scaffold
has been identified to play a secondary role for efficacy, with quinazolines substituted at
the 6-, 7- or 8-position with one chloro group possessing lower MICs against S. aureus.
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These promising results led to efficacy testing of the lead compounds 4.38, 4.45, 4.47 and
4.58 in an in vivo wax moth larva S. aureus model and compounds 4.45 and 4.47 in an in
vivo murine S. aureus model.
All compounds fared better in the wax moth larva study than the untreated versions. On
average, out of ten, 3.83 larvae treated with 5x the MIC survived to the end of the study
while 4.83 treated with 10x the MIC survived. This results in a 55% and 69% respective
survival rate when compared to the DMSO standard.
In the murine model, all treated mice also fared better than the untreated versions. 1x the
MIC for compound 4.47 gave the best results with all mice surviving to the end of the
one week study. 5x the MIC for both compounds 4.45 and 4.47 had five of six mice
survive to the end of the week, giving the next best results and the same as 10 mg/kg of
vancomycin. 10x the MIC for compound 4.47 resulted in the immediate death of five of
the six mice. Additional experiments are required to determine whether these deaths have
been caused due to toxicity or limited solubility during administration of compounds 4.45
and 4.47.
The observed potencies of frontrunner compounds 4.38, 4.45, 4.47 and 4.58 in in vivo
assays make N2,N4-disubstituted quinazoline-2,4-diamines a suitable platform for the
future development of anti-bacterial agents, with a strong focus being on methicillinresistant Staphylococcus aureus.
4.3

Screening of Quinazolines Against ESKAPE Pathogens

With the activity of the quinazoline class of compounds against MRSA, we decided to
test the library of quinazolines against the rest of the ESKAPE pathogens (Enterococcus
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faecium, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and
Enterobacter species) in a high-throughput screen. Testing of 67 quinazolines was
performed with the remaining pathogens (e.g. not MRSA) using MIC assays as described
above. We determined that compound 4.41 from this class was active against A.
baumannii with an MIC of 18.9 µM. The rest of the compounds had MICs >56 µM and
all were inactive to the rest of the ESKAPE pathogens.
4.3.1

Structure-Activity Relationship of Quinazolin-2,4-diamines by Minimum

Inhibitory Concentration
As compound 4.41 was the only active compound, derivatives of this quinazoline were
tested. N4-isopropyl derivative 4.42 and the N4-n-butyl 4.43 were inactive, showing that
small alkyl substituents other than methyl are not active. Thus, a variety of N-benzyl-Nmethylquinazolin-2,4-diamines were synthesized and tested (Table 4.8).
Table 4.8: MICs of N-benzyl-N-methylquinazolin-2,4-diamines against A. baumannii
1403 strain
Structure

4.41

4.68

MIC
(M
18.9

18.9

Structure

MIC
(M
33.5

4.69

Structure

4.71

MIC
(M
3.40

1.67

4.70

The N4-benzyl-N2-methyl derivative 4.68 displayed the same activity as 4.41, showing
that N-benzyl-N-methyl derivation leads to activity against A. baumannii. The N2-n-butyl
4.45 was also inactive in the original assay. Backbone substituted derivatives of 4.41,
however, were found to be active. 7-chloro derivative 4.69 had activity reduced nearly
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two-fold, while 6-derivation to methoxy 4.71 and chloro 4.70 increased the activity
greater than five-and-a-half- and eleven-fold, respectively.
4.3.2

Extended Minimum Inhibitory Concentration Testing

After the initial tests against A. baumanni strain 1403, the active compounds 4.41 and
4.68-4.71 and some similar analogues (4.1, 4.11, 4.14, 4.15 and 4.43) were tested for
MICs against other drug resistant strains of A. baumannii to determine if activity was
shown across a wide range of isolates (Table 4.9). A. baumanni strains A-L were
provided courtesy of Paul Dunman from the University of Rochester Medical Center. The
five original hits 4.41 and 4.68-4.71 were active against the majority of the additional
strains. The 6- and 7-substituted derivatives 4.69-4.71 were active against all thirteen
strains with MICs below 34 µM. Compound 4.71 displayed the best across the board
activity with MICs of 3.4 µM for all strains except against K and L, with MICs of 17 µM.
Three of the compounds (4.11, 4.42 and 4.43) that were inactive against the 1403 strain
were active against at least one of the other twelve strains. Compound 4.11 was active
against the A and B strains with MICs of 39 µM, 4.42 was active against the B strain
with an MIC of 34 µM and 4.43 was active against A, B and D strains with MICs of 3.3
µM, 3.3 µM and 33 µM, respectively.
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Table 4.9: MICs of active compounds and similar compounds against A. baumanni 1403
and A-L strains
MIC (M
Structure

4.1

4.11

4.14

4.15

4.41

4.42

4.43

4.68

4.69

4.70

4.71

1403

A

B

C

D

E

F

G

H

I

J

K

L

>98

>98

>98

>98

>98

>98

>98

>98

>98

>98

>98

>98

>98

>98

39

39

>98

>98

>98

>98

>98

>98

>98

>98

>98

>98

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

>79

18.9

19

38

3.8

38

38

38

38

38

3.8

95

>95

>95

>86

>86

34

>86

>86

>86

>86

>86

>86

>86

>86

>86

>86

>82

3.3

3.3

>82

33

>82

>82

>82

>82

>82

>82

>82

>82

18.9

38

3.8

3.8

95

>95

95

95

38

95

>95

95

95

33.5

6.7

6.7

6.7

3.4

6.7

6.7

5.0

30

6.7

6.7

6.7

3.4

1.67

17

17

8.4

0.3

8.4

8.4

3.3

17

8.4

17

34

8.4

3.40

3.4

3.4

3.4

3.4

3.4

3.4

3.4

3.4

3.4

3.4

17

17
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4.3.3

Minimum Bactericidal Concentrations Activity of Frontrunner Quinazolin-2,4-

Diamines Against Acinetobacter baumannii
MBC testing of 4.41, 4.42, 4.68, 4.70 and 4.71 was performed to determine whether the
compounds were bactericidal or bacteriostatic against A. baumannii 1403 (Figure 4.11).
All tested compounds reduced the percent recovery of cells as the concentration increased
and were thus found to be bactericidal, including compound 4.42 which was completely
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Figure 4.11: Percent recovery curves for A. baumannii 1403 incubated with quinazolines
For 4.41, we observed 0.06% recovery of cells at the MIC of 18.9 µM with an MBC50
value of 3.6 µM and a MBC90 value of 4.3 µM. For 4.42, we observed <6% recovery of
cells at the MIC of >86 µM with an MBC50 value of 2.5 µM and a MBC90 value of 40
µM. For 4.68, we observed 12.67% recovery of cells at the MIC of 18.9 µM with an
MBC50 value of 2.2 µM and a MBC90 value of 5.0 µM. For 4.70, we observed 30%
recovery of cells at the MIC of 1.57 µM with an MBC50 value of 0.85 µM and a MBC90
value of 5.9 µM. Finally, for 4.71, we observed 6.8% recovery of cells at the MIC of 3.40
µM and an MBC50 value of 1.8 µM and a MBC90 value of 9.1 µM. These demonstrate
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that all of the tested N-benzyl-N-methyl-2,4-diaminoquinazolines are broadly bactericidal
in action towards A. baumannii with the MBC50 values for all compounds less than their
MIC.
4.3.4

Determining the Minimum Biofilm Eradication Concentration for 4.41 and 4.68-

4.71
As biofilm formation by A. baumannii is a factor that increases pathogenicity and innate
antibiotic resistance, the active quinazolines 4.41 and 4.68-4.71 were tested for their
capacity to destroy biofilms. Briefly, A. baumannii biofilms were grown in a 96-well
plate, at 37°C for 24 hours. After this time, media was aspirated leaving a biofilm that is
adherent to the walls of the 96-well plate, and replaced with fresh media containing 0X,
0.2X, 0.5X, 1X, 2.5X, 5X or 10X the MIC of relevant compounds. Samples were
incubated at 37°C overnight, before gently being washed twice with sterile PBS, being
careful not to disrupt the biofilm. Buffer was then removed by aspirating and biofilms
were disrupted by the addition of 200 μL of PBS and pipetting samples repeatedly until
all cells were in suspension. This was then serially diluted, and plated for viable colony
forming units. MBEC values were determined by comparison to untreated controls.
Compounds 4.41, 4.68, 4.69 and 4.71 were completely ineffective against biofilms at all
tested concentrations, with greater than 100% recovery of cells at all tested
concentrations. Quinazoline 4.70, however, showed the ability to eradicate cells within
biofilms. At the MIC of 1.67 µM, 46.2% of the cells from the original culture were
recovered while 38.5% of the cells were recovered at the lowest tested concentration
(0.2X the MIC) of 0.33 µM and 15.4% recovery at 8.4 µM (5X the MIC). The MBEC50
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of 0.3 µM and MBEC90 of 3.0 µM show this compound to have anti-biofilm activity at
activities comparable to the MIC.
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Figure 4.12: Percent recovery curve for A. baumannii biofilm grown in the presence of
4.70
4.3.5

Cytotoxicity of 4.70

The cytoxicity of 4.70 was determined against A549 cells and was found to be 16.7 ± 6.0
µM. This gave a selectivity index of 10 when compared to the MIC, showing that this
compound may have therapeutic use in vivo.
4.3.6

In vivo Model of Infection Using Galleria mellonella

The G. mellonella model was used as an initial in vivo study to test the efficacy of
frontrunner quinazolines against A. baumannii. Ten larvae per compound were infected
with 1.0 x 107 A. baumannii. One hour post-infection, 5x the MIC of each compound or
the DMSO vehicle was administered to the worms. An additional group of uninfected
larvae was tested for survivability with DMSO. All infected worms subjected to
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treatment with DMSO were dead within two days, while 80% of the uninfected worms
survived to day 3 (p = 0.0012, Figure 4.10).
Compound 4.41 had 50% of worms survive past the first day (p = 0.0056), while
compound 4.69 had 40% survive (p = 0.214). Compounds 4.68, 4.70 and 4.71 resulted in
70% surviving until day three, with compound 4.68 having 10% die after the first day and
20% after the second (p = 0.0003), while 4.70 (p = 0.0061) and 4.71 (p = 0.002) had all
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Figure 4.13: Wax worm larvae survival post-infection with 5x MIC. * = p < 0.05
A murine model of infection is currently being studied to determine the efficacy of these
compounds in mammalian systems.
4.3.7

Conclusions

Testing of the 67 quinazolines in an in vitro model of A. baumannii infection revealed
one compound 4.41 that displayed activity, a surprisingly low number when compared to
the activity of these agents with MRSA. Screening of analogues of 4.41 revealed five
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quinazolines that were broadly effective against thirteen strains of A. baumannii, with
compound 4.71 displaying activity most consistently. While the other four compounds
were inactive, 4.70 was also found to eradicate biofilms, showing the ability to remove
cells that are generally impervious to antibiotics. The in vivo G. mellonella model of
infection produced results that suggested good in vivo activity for these compounds.
Compounds 4.68, 4.70 and 4.71 had 70% of the wax worms survive, which corresponds
to an 87.5% cure rate when compared to the DMSO model. In summary, the N-benzyl-Nmethylquinazolin-2,4-diamines display excellent in vitro and in vivo efficacy for A.
baumannii treatment as bactericidal agents. This data strongly suggests that these
compounds should be studied further as anti-bacterials.
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Chapter 5: Future Plans
5.1

1,4-Dihydropyridines

5.1.1

Synthesis Going Forward

Analysis of the structure-activity relationship revealed logical compounds to be
synthesized for the further optimization of activity. At the 4- and 7- positions, the use of
unsubstituted phenyl derivatives will allow for the determination of whether or not
substitution is necessary. Derivatives with a 7-O that were highly active, such as 2.31,
2.32, 2.52 and 2.53, will be synthesized as well to see if a corresponding increase in
activity is encountered with the 7-CH2 derivative.
SAR of the 3-position revealed that a smaller alkyl chain has the best activity. Since an
ethyl group was the smallest derivative formed, two new sets will be tested, one with a
methyl ester and the second with the free acid to determine if a smaller ester or the free
acid can be as active as the ethyl ester.
5.1.2

Property-Based Synthesis

Determination of the solubility properties of the pure stereoisomers of 2.1 showed that
the compounds have low aqueous solubilities. A higher aqueous solubility is desirable for
potential therapeutic use and oral bioavailability. As discussed previously, the free acid at
the 3-position will be synthesized. If this molecule retains in vitro activity it should have
an increased solubility compared to an ester derivative.
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The 2-position appears to be an excellent place to attempt modifications based on
properties as derivatives with larger groups have been more active than a simple methyl
group. Determination of the solubilities of oxygen containing derivatives 2.53 and 2.54
may reveal compounds that already have desirable solubilities in place. The solubilites of
compounds 2.1 and 2.2 will also be compared to determine how much of an effect on
solubility the 6-O has on the molecule. As well as these compounds, derivatives can be
synthesized with functional groups that are well known for increasing solubility such as
morpholine. Synthesis of these derivatives can be undertaken from the 1,4dihydrohypyridine by halogenation at the 2-position followed by substitution with a
proper group (Figure 5.1). Derivatives will also be tested baring heteroaryl functionality
at the 4- and 7- positions to see the effects of different aromatic systems, such as pyridyl.

Figure 5.1: Derivation at the 2-position
5.1.3

Additional Testing

Additional property testing should be performed to determine the potential for these
compounds to be successful therapeutic treatments. Pharmacokinetics (PK) and
pharmacodynamics (PD) are important to study because they are used to decipher what
the body does to a compound (PK) and what a compound does to the body (PD).
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Common PK tests are the ADME properties: absorption, distribution, metabolism and
excretion. These properties are used to determine how well a compound acts in the body
and are an excellent description of the potential a compound has for in vivo testing.
Microsomal testing should be performed to see how the compounds can be metabolized
in the body. Identifying sites of oxidation or bond cleavage will allow for modifications
to the structure that will provide for a longer active effect for the compound in the body,
preventing the excretion of a metabolized compound from a body. Oftentimes aryl rings
can be oxidized to phenols by an enzyme and the specific sites can be blocked by
replacing a hydrogen atom with a fluorine with minimal change in activity. Esters and
ethers can often times be cleaved, and if this can be identified early on the functional
groups can be changed, such as replacing the methoxy groups on the 7-phenyl.
Identification of more highly soluble compounds and compounds displaying good PK
properties will lead to compounds that will be valuable as in vivo leads. A murine model
of infection for P. falciparum has been found to be an effective test for initial studies. If
this test leads to good results then further in vivo tests will be performed in a primate
model to determine whether the 1,4-dihydropyridines will make a good platform for
clinical studies.
5.1.4

Stereoselective Syntheses

The stereoselective synthesis of the 1,4-dihydropyridines can be studied as well. The
trans isomer is generally formed in a slight excess due to steric hindrance between the 4and 7- positions, and varying substituents can be tested to see their effect on the ratio.
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Bulkier substituents would reveal whether it is strictly a steric observation while using
strongly electronegative atoms would reveal whether an electronic repulsion is observed.
A revisit of a few stereoselective processes will also occur. Chiral lactone synthesis will
be attempted again, with the replacement of the benzyl proton with a methyl group with
the hopes of isolating enantiopure compounds. The α-β unsaturated lactone may also try
to be resynthesized, as there was a noted difference in ee when pyridine was used as the
base instead of triethylamine. It may be that a suitable base can be found to increase the
ee into the upper ninety percent.
Enantioselective syntheses of the 1,4-dihydropyridine is another method that will be
reevaluated. A chiral hydrazine could be used to set the stereochemistry via the nitrogen
of the pyridine ring. As Enders et al. performed stereoselective syntheses with one
stereocenter, their method may be applied to a series with a second stereocenter.87
Several conditions will be used to see the effects that solvent and temperature have on the
reaction.
5.2

Quinazolines as Anti-Leishmanials

As limited success has been found with the quinazolin-2,4-diamines in in vivo murine
models, studies need to be conducted on the properties of these compounds to determine
if better efficacy can be attained by the synthesis of compounds with more favorable
properties. The microsomal stability should be studied especially since the furan
substituent is a moiety that is well known at being metabolized. Isosteres may need to be
synthesized that keep the biological activity but prevent degradation and increase
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solubility as the active compounds without a furan are generally more hydrophobic with
less favorable aqueous solubility.
5.3

Quinazolines as Antibacterials

As a large number of compounds have been tested, a qualitative structure-activity
relationship (QSAR) study may be appropriate to have a computational method to show
compounds that would have better in vitro activity. QSAR may be able to explain the
lack of highly active compounds bearing dialkyl amine substitutions and shed light on the
more active aryl substituted compounds.
The most active 2,4-diaminoquinazolines in the MRSA assay bore benzyl substituted
amines. These compounds are highly lipophilic and do not have a high aqueous
solubility. Increasing the aqueous solubility should be a priority; derivatives can be made
with more soluble substituents such as hydroxyl or carboxyl substituted benzyl groups.
Pyridyl substitution may also serve to increase the aqueous solubility.
In vivo testing of the lead quinazolines revealed that protection was provided in both a
murine model of infection and a wax worm model of infection. The murine model
followed the test subjects for one week, while the wax worm model observed for three
days. An extended study may provide more data via the observation of whether the
protection will last for a longer period of time. The addition of test compound may be
changed to a time further out than one hour post infection, allowing for the infection to
proceed throughout the animal prior to therapy.
As compound 4.58 was found to be bactericidal at eight times the MIC and was also the
most active quinazoline in vitro, a murine model with this compound should be
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undertaken to determine the efficacy of this compound. Since it is bactericidal, it may
provide more protection than the previously tested quinazolines in vivo.
The only active compounds in the A. baumannii test bore N-benzyl and N-methyl
substitution. The solubility of these compounds are higher than that of the dibenzyl
derivatives in the MRSA study, but there is room for improvement. Aqueous solubility
could be improved via functionality on the benzyl substituent, with testing of the in vitro
properties showing whether the analogues retain activity.
The bactericidal and anti-biofilm activities of the active quinazolin-2,4-diamines reveal a
strong potential for these compounds. A murine model of infection will provide data as to
whether these compounds have potential efficacy in mammals. To go along with these in
vivo tests, PK tests and microsomal stability can help to determine how effective they can
be in vivo. Compound 4.41 (3.15) was tested previously in a murine model of infection
and found to be inactive against L. donovani. The PK and microsomal stability tests can
determine whether the lack of activity is due to the body rendering the compounds
inactive.
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